{"gene":"NOS2","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":1993,"finding":"Molecular cloning of human inducible NOS (NOS2/iNOS) from hepatocytes revealed an 80% amino acid sequence homology to murine macrophage NOS, with recognition sites for FMN, FAD, and NADPH and a consensus calmodulin binding site; unlike the murine macrophage isoform, the human hepatocyte enzyme showed Ca2+ dependence when expressed in 293 kidney cells.","method":"cDNA cloning, heterologous expression in 293 cells, enzymatic assay with Ca2+ chelation and calmodulin antagonist","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — original cloning paper with direct enzymatic characterization and functional validation in transfected cells","pmids":["7682706"],"is_preprint":false},{"year":1993,"finding":"Cloning of inducible NOS from human chondrocytes confirmed a single human iNOS isoform (1153 amino acids, ~131 kDa); CHO cells transfected with this cDNA expressed NOS activity inhibitable by L-arginine analogues, establishing the catalytic competence of the cloned sequence.","method":"cDNA cloning, CHO cell transfection, NOS activity inhibition assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in heterologous cells with inhibitor validation; replicated across multiple human cell types","pmids":["7504305"],"is_preprint":false},{"year":1993,"finding":"Purification and cDNA sequencing of cytokine-induced NOS from a human colorectal adenocarcinoma cell line (DLD-1) confirmed that purified human iNOS shares with murine macrophage iNOS a lack of dependence on exogenous calcium and calmodulin for activity, distinguishing it from brain and endothelial NOS isoforms.","method":"Enzyme purification, calmodulin-independent activity assay, cDNA sequencing","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — purified enzyme with direct biochemical characterization","pmids":["7692964"],"is_preprint":false},{"year":1993,"finding":"NOS2-derived nitric oxide mediates cytokine-induced inhibition of glucose-stimulated insulin secretion by human islets of Langerhans; this was demonstrated by prevention of both cGMP accumulation and nitrite production, and restoration of insulin secretion, by the NOS inhibitor L-NMMA.","method":"Human islet culture, cytokine stimulation, L-NMMA inhibition, nitrite assay, cGMP measurement, insulin secretion assay, EPR spectroscopy","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods establishing mechanistic link between iNOS-derived NO and beta-cell dysfunction","pmids":["8383325"],"is_preprint":false},{"year":1994,"finding":"The human NOS2 gene is approximately 37 kb in length, consists of 26 exons and 25 introns, and is located on chromosome 17 at position 17cen-q11.2; primer extension mapped the transcriptional initiation site 30 bp downstream of a TATA sequence, and cytokine-inducible promoter elements reside within a ~400 bp 5'-flanking region.","method":"Genomic library screening, exon-intron mapping, primer extension, FISH, somatic cell hybrid PCR panel","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — comprehensive structural genomic characterization with independent chromosomal localization methods","pmids":["7509810"],"is_preprint":false},{"year":1994,"finding":"Constitutive NOS2 (iNOS) expression occurs in Epstein-Barr virus-transformed human B lymphocytes; NOS2-derived NO maintains EBV latency by down-regulating expression of the immediate-early EBV transactivator Zta and also inhibits apoptosis in B lymphocyte cell lines through cGMP-independent, redox/sulfhydryl-dependent mechanisms.","method":"RT-PCR, NOS activity assay, EBV reactivation assay, apoptosis assay, cGMP-independent pathway analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — multiple functional readouts linking constitutive iNOS activity to EBV latency and cell survival","pmids":["7528106"],"is_preprint":false},{"year":1994,"finding":"Continuous, constitutive expression of NOS2 (iNOS) in normal human airway epithelial cells in vivo was demonstrated by molecular cloning; expression was dependent on the in vivo airway environment, was abolished upon cell removal, and was decreased by inhaled corticosteroids and β-adrenergic agonists.","method":"Molecular cloning, in situ hybridization, NOS activity quantitation in epithelial cell lysates, in vivo pharmacological inhibition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — direct cloning from airway tissue with quantitative activity measurement and in vivo pharmacological modulation","pmids":["7544004"],"is_preprint":false},{"year":1996,"finding":"Transcriptional activation of the human NOS2 gene by cytokines (TNF-α, IL-1β, IFN-γ) was demonstrated by nuclear run-on analysis; functional cytokine-responsive promoter elements were identified in three distinct regions located between −3.8 and −16 kb upstream of the gene, markedly distinct from the murine iNOS promoter where only 1 kb of 5'-flanking sequence is required.","method":"Nuclear run-on transcription assay, luciferase reporter transfection with deletion constructs up to −16 kb","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — nuclear run-on plus systematic promoter deletion analysis","pmids":["8577713"],"is_preprint":false},{"year":1999,"finding":"Crystal structures of human iNOS catalytic (heme) domain at 2.25 Å revealed active-site residues nearly identical to those of eNOS; both structures show a structural zinc atom at the dimer interface coordinated by four cysteines (two from each monomer), establishing this zinc-tetrathiolate center as a conserved element of NOS dimer stability.","method":"X-ray crystallography at 2.25 Å resolution, comparison with eNOS structure","journal":"Nature structural biology","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with cross-isoform structural comparison","pmids":["10074942"],"is_preprint":false},{"year":1999,"finding":"Crystal structures of the heme domain of human NOS2 in zinc-free and zinc-bound states revealed that: (i) in the zinc-free form, two symmetry-related cysteines form a disulfide bond; (ii) in the zinc-bound form, the same cysteines constitute a ZnS4 (zinc-tetrathiolate) center identical to that in NOS3, which stabilizes intersubunit contacts and maintains the integrity of the tetrahydrobiopterin (BH4) binding site.","method":"X-ray crystallography of zinc-free and zinc-bound NOS2 heme domain, structural comparison with NOS3","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — two independent crystal structures with explicit functional interpretation of zinc coordination","pmids":["10409685"],"is_preprint":false},{"year":1996,"finding":"Functional promoter analysis with constructs linked to the thymidine kinase promoter identified that the human NOS2 gene requires promoter sequences up to −16 kb for full cytokine inducibility; the human iNOS promoter architecture contrasts substantially with the murine promoter, which requires only ~1 kb.","method":"Luciferase reporter assays with NOS2-TK promoter fusions up to −16 kb in cytokine-stimulated AKN-1 hepatic cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — systematic promoter deletion analysis with quantitative reporter readout","pmids":["8577713"],"is_preprint":false},{"year":2002,"finding":"Histone deacetylase 2 (HDAC2) directly interacts with NF-κB p65 and promotes cytokine-induced NOS2 transcription; HDAC inhibition with trichostatin A suppressed iNOS promoter activity without altering NF-κB DNA binding, and HDAC2 overexpression enhanced both NOS2 and NF-κB element promoter activity.","method":"Co-immunoprecipitation, GST pull-down, transient transfection reporter assays, Griess reaction for NO, gel shift/supershift assays","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP and direct GST pull-down identifying HDAC2–p65 interaction, with multiple functional readouts","pmids":["12138131"],"is_preprint":false},{"year":2002,"finding":"NOS2 protein expressed in skeletal muscle of septic patients undergoes tyrosine nitration by peroxynitrite on selected tyrosine residues, and in vitro nitration of NOS2 by peroxynitrite decreases its enzymatic activity, identifying tyrosine nitration as a post-translational mechanism of NOS2 self-inhibition.","method":"In vitro peroxynitrite treatment, Western blot, immunoprecipitation, NOS activity assay in human skeletal muscle from septic patients","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 — direct in vitro enzyme inactivation correlated with in vivo nitration, but single-lab study","pmids":["12097137"],"is_preprint":false},{"year":2001,"finding":"An S714P mutation in NOS2 identified in Dahl/Rapp salt-sensitive rats reduces enzyme stability post-translationally (shorter protein half-life), resulting in decreased NOS2 protein levels and reduced nitrite production; a proteasomal mechanism is implicated, and the functional deficit is overcome by L-arginine supplementation.","method":"Transient transfection of COS-7 cells with wild-type and mutant NOS2 cDNA, metabolic labeling (pulse-chase), immunoblot, nitrite production assay","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in heterologous cells with metabolic labeling establishing reduced half-life as mechanism","pmids":["11509447"],"is_preprint":false},{"year":2007,"finding":"NOS2-derived NO regulates NF-κB activity by S-nitrosylating the p65 subunit at a conserved cysteine within the Rel homology domain; this inhibits NF-κB-dependent gene transcription, and nuclear levels of S-nitrosylated p65 correlate with decreased p50-p65 DNA binding, establishing a negative feedback loop in which NOS2 attenuates its own expression.","method":"S-nitrosylation detection, site-directed mutagenesis of p65 cysteine, NF-κB reporter assays, ChIP for NOS2 promoter binding, cytokine stimulation of respiratory epithelial cells and macrophages","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct identification of S-nitrosylation site by mutagenesis, multiple orthogonal methods including ChIP","pmids":["17720813"],"is_preprint":false},{"year":2008,"finding":"Crystal structures of NOS isoforms with inhibitor-bound conformations revealed an isozyme-specific induced-fit binding mode: a cascade of conformational changes in second- and third-shell residue triads opens an isoform-specific specificity pocket; this 'anchored plasticity' mechanism provides the structural basis for selective iNOS inhibitor design.","method":"X-ray crystallography of NOS-inhibitor complexes, mutagenesis of second/third-shell residues, inhibitor binding assays","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 — multiple crystal structures combined with mutagenesis establishing induced-fit mechanism","pmids":["18849972"],"is_preprint":false},{"year":1998,"finding":"iNOS (NOS2) is required for normal wound closure; iNOS knockout mice show a 31% delay in excisional wound repair that is fully reversed by single topical application of an adenoviral vector expressing human iNOS cDNA, establishing a direct, gene-specific role for iNOS-derived NO in wound healing.","method":"iNOS knockout mice, adenoviral gene transfer (AdiNOS), wound closure measurement, RT-PCR for iNOS mRNA, pharmacological iNOS inhibition","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout rescued by gene replacement, with pharmacological corroboration","pmids":["9486966"],"is_preprint":false},{"year":2001,"finding":"iNOS-deficient fibroblasts exhibit reduced proliferation, decreased collagen synthesis, and slower matrix contraction compared to wild-type; collagen synthesis is restored by NO donors, demonstrating that iNOS-derived NO is required cell-autonomously for fibroblast functions critical to wound healing.","method":"iNOS knockout mouse fibroblast explant culture, [3H]-thymidine incorporation, [3H]-proline incorporation into collagenase-sensitive protein, fibroblast-populated collagen lattice contraction assay, NO donor rescue","journal":"Surgery","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with multiple cellular phenotypes and chemical rescue","pmids":["11490353"],"is_preprint":false},{"year":2006,"finding":"Genetic deletion of NOS2 in APP Swedish mutant mice results in hyperphosphorylation of mouse tau, its redistribution to somatodendritic compartments, and aggregate formation, as well as increased insoluble Aβ, neuronal degeneration, and caspase-3 activation; NO acts at a junction point connecting Aβ pathology, caspase activation, and tau aggregation.","method":"Bigenic mouse model (APP/NOS2−/−), immunohistochemistry, Western blot, tau phosphorylation assays, caspase-3 activation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in bigenic knockout model with multiple molecular phenotypes","pmids":["16908860"],"is_preprint":false},{"year":2013,"finding":"Proteomic analysis of the NOS2 interactome in human airway epithelial cells identified FBXO45 as a novel direct NOS2 interactor that requires Asn27 in the 23DINNN27 motif of NOS2 (same as SPSB proteins) but recruits a distinct E3 ubiquitin ligase complex (MYCBP2/SKP1); cytokine-inducible NOS2 interactions with allosteric activators and the ubiquitin-proteasome system correlated with increased NOS2 ubiquitination and NO output.","method":"Flag-tag Co-IP, SILAC quantitative MS, direct interaction validation, cytokine stimulation, NOS2 ubiquitination assay","journal":"Nitric oxide : biology and chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — SILAC interactome plus direct interaction validation with motif mutagenesis implied by comparison with SPSB data","pmids":["23438482"],"is_preprint":false},{"year":2013,"finding":"iNOS is targeted to peroxisomes in hepatocytes through interaction with the peroxisomal import protein PEX7 and the adaptor protein EBP50; siRNA knockdown of PEX7 reduced iNOS–peroxisomal colocalization, and iNOS peroxisomal targeting was contingent on EBP50 expression in LPS-treated mice, identifying a novel subcellular targeting pathway for NOS2.","method":"siRNA knockdown, confocal microscopy, immunoelectron microscopy, MALDI-MS proteomics, Co-IP, in vivo LPS model","journal":"Nitric oxide : biology and chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (EM, confocal, MS, siRNA) confirming peroxisomal localization mechanism in vitro and in vivo","pmids":["23474170"],"is_preprint":false},{"year":2016,"finding":"iNOS-generated NO is required for transdifferentiation of fibroblasts to endothelial cells; upon NFκB-dependent iNOS induction, iNOS translocates to the nucleus and S-nitrosylates the polycomb repressive complex member RING1A at Cys398, reducing RING1A chromatin binding and global H3K27 trimethylation; expression of a C398A RING1A mutant nearly abolished transdifferentiation.","method":"iNOS KO murine embryonic fibroblasts, siRNA knockdown, iNOS overexpression, immunostaining for nuclear iNOS, Co-IP, mass spectrometry for S-nitrosylation site, H3K27me3 ChIP, transdifferentiation efficiency assay","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1-2 — site-specific S-nitrosylation identified by MS and confirmed by mutagenesis, combined with genetic KO and rescue","pmids":["27623813"],"is_preprint":false},{"year":2016,"finding":"In TLR4-activated microglia, de novo upregulated Sur1-Trpm4 channels regulate NOS2 transcription via the calcineurin (CN)/NFAT pathway; pharmacological or genetic inhibition of Sur1-Trpm4 increased [Ca2+]i but caused phosphorylation of CaMKII and CN (inactivating CN), reduced NFAT nuclear translocation, and suppressed NOS2 mRNA and protein, as confirmed by chromatin immunoprecipitation.","method":"In vivo and in vitro microglia from WT, Abcc8−/−, Trpm4−/− mice; siRNA gene silencing; patch clamp; calcium imaging; ChIP for NFAT at Nos2 promoter; Griess assay; qPCR; Western blot","journal":"Journal of neuroinflammation","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic models, ChIP, and electrophysiology establishing Sur1-Trpm4→CN/NFAT→NOS2 pathway","pmids":["27246103"],"is_preprint":false},{"year":2022,"finding":"LACC1 converts L-citrulline (the NOS2 byproduct) to L-ornithine and isocyanic acid, bridging NOS2 activity to polyamine biosynthesis (via ODC1) in inflammatory macrophages; LACC1 phenotypes in Salmonella-infected bone marrow-derived macrophages required upstream NOS2 and downstream ODC1, and chemical complementation with L-ornithine rescued Lacc1−/− activity.","method":"Lacc1−/−, Nos2−/−, Odc1−/− mouse models; bone marrow-derived macrophage Salmonella infection; biochemical enzyme assay; L-ornithine complementation; genetic epistasis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — enzyme reconstitution identifying the L-citrulline→L-ornithine reaction, supported by genetic epistasis across three knockout models and chemical rescue","pmids":["35978195"],"is_preprint":false},{"year":2022,"finding":"NOS2 expression and associated NO signaling induces DNA hypomethylation by promoting degradation of DNMT1 through an NO/p38-MAPK/KAT5-dependent mechanism; this results in LINE-1 retrotransposon hypomethylation, expression, DNA damage, and malignant epithelial transformation.","method":"NOS2 overexpression and knockout in human cell lines, NO donor treatment, DNMT1 protein stability assay, p38-MAPK inhibition, KAT5 pathway analysis, bisulfite sequencing, LINE-1 expression and DNA damage assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — mechanistic pathway defined by multiple inhibitors and genetic tools with direct measurement of DNMT1 degradation and epigenetic outputs","pmids":["35584114"],"is_preprint":false},{"year":1999,"finding":"A polymorphic (CCTTT)n pentanucleotide repeat in the NOS2A promoter differentially drives NOS2 transcription; the 14-repeat allele showed strongest IL-1β-inducible luciferase activity and was least inhibited by high-glucose conditions, demonstrating that promoter microsatellite length functionally modulates NOS2 expression.","method":"Luciferase reporter assay in transfected colonic carcinoma cells with different (CCTTT)n repeat constructs under IL-1β stimulation and high-glucose conditions","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — direct functional promoter assay; single-lab study in one cell type","pmids":["10506586"],"is_preprint":false},{"year":2002,"finding":"Rho GTPase signaling regulates NOS2 at a post-transcriptional level: inhibition of ROCK (Rho-associated kinase) with Y-27632 decreased NOS2 promoter activity yet increased NOS2 mRNA and protein levels, indicating that ROCK-mediated suppression operates downstream of transcription initiation at the message and protein level, independently of prenylation-mediated effects on the NOS2 promoter.","method":"Pharmacological inhibition of HMG-CoA reductase, geranylgeranyl pyrophosphate rescue, ROCK inhibitor (Y-27632), NOS2 promoter-luciferase, NOS2 mRNA and protein quantitation in human alveolar epithelial cells","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pathway inhibitors dissecting promoter vs. post-transcriptional regulation; single-lab study","pmids":["12169580"],"is_preprint":false},{"year":2020,"finding":"A homozygous frameshift mutation in NOS2 causing a truncated, catalytically inactive NOS2 protein (no NO production) was identified in a human patient with fatal CMV disease, establishing that inherited NOS2 deficiency causes selective susceptibility to CMV in humans while being otherwise clinically silent.","method":"Whole-exome sequencing, functional testing of truncated mutant (no NO production), population-level analysis of NOS2 homozygous variants in public databases","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 1-2 — human genetic loss-of-function with direct demonstration of absent enzymatic activity","pmids":["31995689"],"is_preprint":false},{"year":2012,"finding":"NOS2 enhances KRAS-driven lung tumorigenesis: KRAS(G12D);NOS2 knockout mice showed delayed lung tumor development, reduced tumor cell proliferation, suppressed macrophage recruitment, and markedly decreased miR-21 expression in lung carcinomas compared to KRAS(G12D);NOS2 wild-type controls, demonstrating cooperative action of NOS2 and oncogenic KRAS in driving lung cancer via miR-21-dependent Ras signaling amplification.","method":"Genetic crosses of NOS2 KO with KRAS(G12D) mouse model, tumor histology, proliferation assays, macrophage infiltration analysis, qRT-PCR, in situ hybridization for miR-21","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 2 — clean genetic epistasis in transgenic cancer model with multiple defined molecular phenotypes","pmids":["22618808"],"is_preprint":false},{"year":2018,"finding":"In a mannan-induced psoriatic arthritis mouse model, macrophage NOS2-derived NO promotes arthritis by triggering IL-1α release from skin macrophages, which then drives IL-17 production by innate lymphoid cells; Nos2 deletion or pharmacological NOS inhibition (L-NAME) suppressed disease, placing NOS2 upstream of IL-1α and the IL-17 innate lymphocyte axis.","method":"Nos2−/− mice, mannan-induced psoriatic arthritis model, Nos2-selective and general NOS inhibitors, IL-1α and IL-17 quantitation, monocyte subset analysis from PsA patients","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout combined with pharmacological inhibition and mechanistic cytokine pathway placement","pmids":["29774240"],"is_preprint":false},{"year":2014,"finding":"NOS2 in ER-negative breast cancer cells is feed-forward regulated by hypoxia, serum withdrawal, IFN-γ, and exogenous NO; NOS2-derived NO upregulates S100A8, IL-6, IL-8, and TIMP-1, enhances cellular migration and chemoresistance to Taxol, and promotes brain metastasis; NOS2 inhibition in MDA-MB-231 xenografts suppressed tumor growth and metastasis.","method":"NOS2 inhibitor treatment and shRNA knockdown in ER− breast cancer cells, xenograft mouse model, fat-pad-to-brain metastasis assay, cytokine/chemokine profiling, Taxol chemoresistance assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — in vitro mechanistic studies corroborated by in vivo xenograft genetic/pharmacological experiments","pmids":["24733928"],"is_preprint":false},{"year":2011,"finding":"NOS2-derived NO mediates glioma stem cell (GSC) proliferation and tumorigenicity; NOS2 is elevated in GSCs relative to non-GSCs and normal progenitors, NOS2 inhibition selectively impairs GSC growth and intracranial tumor formation, and NOS2-regulated genes include the cell-cycle inhibitor CDA1.","method":"NOS2 inhibitor (1400W) treatment, NOS2 shRNA in GSC cultures, murine intracranial glioma model, gene expression profiling, CDA1 identification","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — multiple loss-of-function approaches in vitro and in vivo with pathway gene identification","pmids":["21729780"],"is_preprint":false}],"current_model":"NOS2 (iNOS) is a calcium-independent, transcriptionally inducible enzyme that converts L-arginine to NO and L-citrulline using FMN, FAD, NADPH, heme, and tetrahydrobiopterin cofactors; its homodimer is stabilized by a zinc-tetrathiolate center; it is transcriptionally activated by NF-κB, STAT-1α, NFAT (via Sur1-Trpm4/calcineurin signaling), and HDAC2–NF-κB complexes through promoter elements up to −16 kb in humans, and is post-transcriptionally regulated by a network of RNA-binding proteins; NOS2 activity is subject to negative feedback via S-nitrosylation of NF-κB p65 (at a conserved Rel-domain cysteine) and auto-nitration of NOS2 tyrosine residues by peroxynitrite; NOS2 protein stability is regulated post-translationally (proteasomal degradation via FBXO45/MYCBP2 E3 complex; S714 phosphorylation status); subcellular targeting to peroxisomes is mediated by PEX7 and EBP50; NOS2-derived NO exerts pleiotropic downstream effects including S-nitrosylation of RING1A to relieve polycomb-mediated epigenetic repression during transdifferentiation, DNMT1 degradation via p38-MAPK/KAT5 causing DNA hypomethylation and LINE-1 retrotransposon activation, bridging to polyamine metabolism through LACC1-mediated conversion of L-citrulline to L-ornithine, and negative feedback on NF-κB; physiologically, NOS2 is required for wound healing (collagen synthesis, fibroblast proliferation, matrix contraction), bone fracture repair, anti-CMV immunity, and suppression of tau hyperphosphorylation, while pathologically driving neuroinflammation, psoriatic arthritis (via macrophage IL-1α→innate lymphocyte IL-17), and cancer progression in KRAS-mutant lung cancer and ER-negative breast cancer."},"narrative":{"teleology":[{"year":1993,"claim":"Molecular cloning from multiple human tissues established that a single human iNOS isoform (NOS2) exists, resolving uncertainty about whether humans express a functional inducible NOS and defining its cofactor requirements (FMN, FAD, NADPH) and calcium-independent catalysis.","evidence":"cDNA cloning from hepatocytes, chondrocytes, and DLD-1 cells with heterologous expression in 293 and CHO cells and purified enzyme assays","pmids":["7682706","7504305","7692964"],"confidence":"High","gaps":["Calmodulin binding was identified by sequence but its structural role in constitutive activation was not resolved","Tissue-specific splice variants were not excluded"]},{"year":1993,"claim":"NOS2-derived NO was linked to a specific pathophysiological effector function — cytokine-induced suppression of glucose-stimulated insulin secretion in human islets — establishing NO as a mediator of beta-cell dysfunction.","evidence":"Human islet culture with cytokine stimulation, L-NMMA inhibition, nitrite assay, cGMP measurement, and EPR spectroscopy","pmids":["8383325"],"confidence":"High","gaps":["Downstream NO targets in beta cells not identified","Relative contributions of cGMP-dependent vs. cGMP-independent NO signaling not dissected"]},{"year":1994,"claim":"Genomic characterization and in vivo expression studies revealed the human NOS2 gene structure (26 exons, chromosome 17q) and showed that constitutive NOS2 expression occurs in airway epithelium and EBV-transformed B cells, overturning the assumption that NOS2 is exclusively inducible.","evidence":"Genomic library screening, FISH mapping, in situ hybridization of airway epithelium, RT-PCR/NOS activity in EBV-transformed B cells","pmids":["7509810","7544004","7528106"],"confidence":"High","gaps":["Mechanisms sustaining constitutive expression in airway epithelium not defined","Whether constitutive expression reflects tonic cytokine signaling was unresolved"]},{"year":1996,"claim":"Systematic promoter analysis revealed that full cytokine inducibility of human NOS2 requires upstream sequences extending to −16 kb — far beyond the ~1 kb murine promoter — identifying three distinct cytokine-responsive regions and explaining prior difficulty in reconstituting human iNOS induction.","evidence":"Nuclear run-on assays and luciferase reporter constructs with deletions up to −16 kb in cytokine-stimulated AKN-1 hepatic cells","pmids":["8577713"],"confidence":"High","gaps":["Specific transcription factors binding the distal elements were not identified","Chromatin architecture at the extended locus not characterized"]},{"year":1999,"claim":"Crystal structures of the NOS2 heme domain revealed a zinc-tetrathiolate center at the dimer interface that stabilizes intersubunit contacts and maintains the tetrahydrobiopterin binding site, providing the first structural framework for NOS dimerization and cofactor coupling.","evidence":"X-ray crystallography at 2.25 Å of zinc-free and zinc-bound human iNOS heme domains, comparison with eNOS","pmids":["10074942","10409685"],"confidence":"High","gaps":["Full-length holoenzyme structure was not obtained","Conformational dynamics during catalytic cycling not addressed"]},{"year":1999,"claim":"A polymorphic (CCTTT)n pentanucleotide repeat in the NOS2 promoter was shown to modulate transcriptional output, with the 14-repeat allele conferring maximal IL-1β-inducible activity, linking NOS2 promoter microsatellite variation to functional expression differences.","evidence":"Luciferase reporter assays with different repeat-length constructs in colonic carcinoma cells under IL-1β and high-glucose conditions","pmids":["10506586"],"confidence":"Medium","gaps":["Single cell type tested","In vivo relevance of repeat-length variation not demonstrated","Mechanism by which repeat length influences transcription factor binding not defined"]},{"year":1998,"claim":"Genetic loss-of-function in mice established that NOS2-derived NO is required for wound healing, directly linking iNOS to collagen synthesis, fibroblast proliferation, and matrix contraction — effects rescued by adenoviral NOS2 gene transfer or NO donors.","evidence":"iNOS knockout mice with wound closure assays, adenoviral rescue, and iNOS−/− fibroblast cultures with NO donor complementation","pmids":["9486966","11490353"],"confidence":"High","gaps":["Molecular targets of NO in fibroblast collagen synthesis not identified","Relative contributions of macrophage vs. fibroblast NOS2 not separated in vivo"]},{"year":2001,"claim":"An S714P mutation in NOS2 was shown to reduce enzyme stability by accelerating proteasomal degradation, establishing that post-translational protein turnover is a critical determinant of NOS2 activity levels.","evidence":"Pulse-chase metabolic labeling in COS-7 cells expressing wild-type vs. S714P NOS2, immunoblot, nitrite assay","pmids":["11509447"],"confidence":"High","gaps":["The specific E3 ligase responsible was not identified at this time","Whether S714 phosphorylation state regulates wild-type turnover was not tested"]},{"year":2002,"claim":"Two post-translational regulatory mechanisms were defined: HDAC2 was identified as a coactivator of NF-κB-dependent NOS2 transcription via direct p65 interaction, and peroxynitrite-mediated tyrosine nitration of NOS2 was shown to decrease its enzymatic activity, establishing auto-inhibitory feedback.","evidence":"Co-IP/GST pull-down for HDAC2–p65, reporter assays; in vitro peroxynitrite treatment with NOS activity assay in human skeletal muscle","pmids":["12138131","12097137"],"confidence":"High","gaps":["Specific nitrated tyrosine residues not mapped","HDAC2 recruitment mechanism to the NOS2 promoter in chromatin context not resolved"]},{"year":2002,"claim":"Rho/ROCK signaling was identified as a post-transcriptional regulator of NOS2, with ROCK inhibition paradoxically increasing NOS2 mRNA and protein despite reducing promoter activity, revealing a previously unrecognized layer of regulation downstream of transcription.","evidence":"ROCK inhibitor (Y-27632) and HMG-CoA reductase inhibitor in human alveolar epithelial cells, promoter-luciferase vs. mRNA/protein analysis","pmids":["12169580"],"confidence":"Medium","gaps":["Identity of RNA-binding proteins or mRNA stability factors mediating ROCK effects unknown","Not replicated in other cell types"]},{"year":2006,"claim":"Genetic deletion of NOS2 in APP transgenic mice caused tau hyperphosphorylation, somatodendritic redistribution, and neurodegeneration, positioning NOS2-derived NO as a suppressor of tau pathology and connecting NO to the intersection of amyloid and tau biology.","evidence":"APP/NOS2−/− bigenic mice, immunohistochemistry, tau phosphorylation and aggregation assays, caspase-3 activation","pmids":["16908860"],"confidence":"High","gaps":["Direct molecular target of NO that modulates tau phosphorylation not identified","Whether the effect is cGMP-dependent or S-nitrosylation-mediated was unknown"]},{"year":2007,"claim":"S-nitrosylation of NF-κB p65 at a conserved Rel-domain cysteine by NOS2-derived NO was shown to inhibit NF-κB DNA binding and NOS2 promoter activity, establishing the molecular basis of a negative feedback loop through which NOS2 attenuates its own transcription.","evidence":"S-nitrosylation detection, site-directed mutagenesis of p65 cysteine, NF-κB reporter assays, ChIP in respiratory epithelial cells and macrophages","pmids":["17720813"],"confidence":"High","gaps":["Kinetics and reversibility of p65 S-nitrosylation in vivo not determined","Whether denitrosylases regulate this feedback is unknown"]},{"year":2008,"claim":"Crystal structures of NOS-inhibitor complexes revealed an isoform-specific induced-fit mechanism ('anchored plasticity') involving second- and third-shell residue triads, providing the structural rationale for designing selective iNOS inhibitors.","evidence":"X-ray crystallography of multiple NOS-inhibitor complexes, mutagenesis of specificity-determining residues","pmids":["18849972"],"confidence":"High","gaps":["In vivo pharmacokinetic validation of selectivity not reported","Whether the induced-fit mechanism operates similarly in the full-length holoenzyme is unknown"]},{"year":2011,"claim":"NOS2 was shown to sustain glioma stem cell proliferation and tumorigenicity, with NOS2 inhibition selectively impairing GSC growth and intracranial tumor formation, identifying NOS2 as a therapeutic vulnerability in glioblastoma.","evidence":"NOS2 inhibitor (1400W) and shRNA in GSC cultures, murine intracranial glioma model, gene expression profiling","pmids":["21729780"],"confidence":"High","gaps":["Direct NO targets in GSC self-renewal not defined","Whether NOS2 is essential in non-GSC tumor bulk was not addressed"]},{"year":2012,"claim":"Genetic epistasis showed that NOS2 cooperates with oncogenic KRAS to drive lung tumorigenesis via miR-21-dependent Ras signaling amplification, connecting iNOS-derived NO to a specific oncogenic pathway.","evidence":"KRAS(G12D)/NOS2 KO mouse crosses, tumor histology, proliferation assays, miR-21 quantitation","pmids":["22618808"],"confidence":"High","gaps":["Mechanism by which NO upregulates miR-21 not defined","Relevance to human KRAS-mutant lung adenocarcinoma not directly tested"]},{"year":2013,"claim":"Two key aspects of NOS2 protein regulation were resolved: FBXO45/MYCBP2 was identified as a novel E3 ubiquitin ligase complex targeting NOS2 for proteasomal degradation, and PEX7/EBP50 were shown to mediate NOS2 targeting to peroxisomes, revealing unexpected subcellular compartmentalization.","evidence":"SILAC quantitative MS interactome in airway epithelial cells, Flag-tag Co-IP, siRNA knockdown of PEX7, confocal/immunoelectron microscopy, in vivo LPS model","pmids":["23438482","23474170"],"confidence":"High","gaps":["Functional consequence of peroxisomal NOS2 on local NO signaling not characterized","Whether FBXO45-mediated degradation is regulated by cytokine signaling remains to be dissected"]},{"year":2014,"claim":"NOS2 was shown to drive ER-negative breast cancer aggressiveness by upregulating pro-metastatic factors (S100A8, IL-6, IL-8, TIMP-1), enhancing migration, chemoresistance, and brain metastasis, positioning NOS2 as a therapeutic target in aggressive breast cancer.","evidence":"NOS2 inhibitor and shRNA in MDA-MB-231 cells, xenograft model, fat-pad-to-brain metastasis assay, cytokine profiling","pmids":["24733928"],"confidence":"High","gaps":["Direct NO signaling pathway linking NOS2 to S100A8/IL-6 upregulation not defined","Patient-derived xenograft validation not reported"]},{"year":2016,"claim":"Two new signaling pathways converging on NOS2 were defined: Sur1-Trpm4 channels were shown to regulate NOS2 transcription via calcineurin/NFAT in microglia, and NOS2-derived NO was found to S-nitrosylate RING1A at Cys398 to relieve polycomb repression during fibroblast-to-endothelial transdifferentiation, revealing NOS2 as an epigenetic regulator.","evidence":"Abcc8−/−, Trpm4−/− microglia with patch clamp, calcium imaging, ChIP for NFAT; iNOS KO fibroblasts with mass spectrometry for RING1A S-nitrosylation site, C398A mutagenesis, H3K27me3 ChIP","pmids":["27246103","27623813"],"confidence":"High","gaps":["Genome-wide targets of RING1A derepression by NO not catalogued","Whether Sur1-Trpm4/NFAT axis operates in human microglia not tested"]},{"year":2018,"claim":"NOS2 was positioned upstream of an IL-1α→IL-17 innate lymphoid cell axis in psoriatic arthritis, with macrophage NOS2-derived NO triggering IL-1α release that drives pathogenic IL-17 production.","evidence":"Nos2−/− mice, mannan-induced psoriatic arthritis model, pharmacological NOS inhibition, cytokine quantitation, PsA patient monocyte analysis","pmids":["29774240"],"confidence":"High","gaps":["Mechanism of NO-induced IL-1α release from macrophages not molecularly defined","Human genetic evidence linking NOS2 variants to PsA not available"]},{"year":2020,"claim":"A human NOS2 loss-of-function frameshift mutation causing absent NO production was linked to fatal CMV disease, establishing that NOS2 is essential for anti-CMV immunity in humans while being dispensable for other immune functions.","evidence":"Whole-exome sequencing, functional testing of truncated NOS2 mutant, population-level variant analysis","pmids":["31995689"],"confidence":"High","gaps":["Whether heterozygous NOS2 deficiency confers partial susceptibility unknown","Mechanism by which NOS2-derived NO controls CMV replication in humans not defined"]},{"year":2022,"claim":"Two downstream effector pathways of NOS2 were elucidated: LACC1 was shown to convert the NOS2 byproduct L-citrulline to L-ornithine, bridging NO synthesis to polyamine metabolism in macrophages, and NOS2-derived NO was found to promote DNMT1 degradation via p38-MAPK/KAT5, causing LINE-1 hypomethylation and genomic instability.","evidence":"Lacc1−/−, Nos2−/−, Odc1−/− macrophages with Salmonella infection and chemical rescue; NOS2 overexpression/KO with DNMT1 stability assay, bisulfite sequencing, LINE-1 assays","pmids":["35978195","35584114"],"confidence":"High","gaps":["Whether LACC1 pathway is relevant in non-macrophage cell types unknown","Quantitative contribution of NOS2-driven DNMT1 loss to cancer initiation vs. progression not separated"]},{"year":null,"claim":"Key unresolved questions include the full-length holoenzyme structure of human NOS2, the identity of RNA-binding proteins mediating post-transcriptional regulation, the direct NO targets controlling tau phosphorylation, and the mechanism by which NOS2-derived NO triggers IL-1α release from macrophages.","evidence":"","pmids":[],"confidence":"High","gaps":["No full-length human NOS2 holoenzyme structure available","Post-transcriptional regulatory network (RNA-binding proteins, miRNA) incompletely defined","Molecular mechanism of NO-mediated suppression of tau hyperphosphorylation unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[14,21]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0005777","term_label":"peroxisome","supporting_discovery_ids":[20]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[21]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[16,17,27,29]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[14,22,24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[28,30,31]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[21,24]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[23]}],"complexes":[],"partners":["NFKB1","RELA","HDAC2","FBXO45","MYCBP2","PEX7","SLC9A3R1","RING1"],"other_free_text":[]},"mechanistic_narrative":"NOS2 (inducible nitric oxide synthase, iNOS) is a calcium-independent homodimeric enzyme that oxidizes L-arginine to nitric oxide (NO) and L-citrulline using FMN, FAD, NADPH, heme, and tetrahydrobiopterin cofactors, with dimer stability maintained by a zinc-tetrathiolate center at the subunit interface [PMID:10074942, PMID:10409685]. Transcription of the human NOS2 gene requires cytokine-responsive promoter elements extending up to −16 kb and is driven by NF-κB, STAT-1α, NFAT (via Sur1-Trpm4/calcineurin signaling), and HDAC2–NF-κB complexes, while NOS2-derived NO feeds back to inhibit its own expression through S-nitrosylation of NF-κB p65 at a conserved Rel-domain cysteine [PMID:8577713, PMID:12138131, PMID:27246103, PMID:17720813]. NOS2 protein turnover is regulated by proteasomal degradation via the FBXO45/MYCBP2 E3 ubiquitin ligase complex, and NOS2 is targeted to peroxisomes through PEX7 and EBP50 [PMID:23438482, PMID:23474170]. Downstream, NOS2-derived NO drives wound healing, collagen synthesis, and fibroblast proliferation [PMID:9486966, PMID:11490353], bridges to polyamine metabolism via LACC1-mediated conversion of L-citrulline to L-ornithine [PMID:35978195], S-nitrosylates RING1A to relieve polycomb-mediated epigenetic repression during transdifferentiation [PMID:27623813], promotes DNMT1 degradation and LINE-1 retrotransposon activation via p38-MAPK/KAT5 [PMID:35584114], and contributes to oncogenesis in KRAS-mutant lung cancer and ER-negative breast cancer [PMID:22618808, PMID:24733928]; inherited complete NOS2 deficiency in humans causes selective susceptibility to cytomegalovirus disease [PMID:31995689]."},"prefetch_data":{"uniprot":{"accession":"P35228","full_name":"Nitric oxide synthase, inducible","aliases":["Hepatocyte NOS","HEP-NOS","Inducible NO synthase","Inducible NOS","iNOS","NOS type II","Peptidyl-cysteine S-nitrosylase NOS2"],"length_aa":1153,"mass_kda":131.1,"function":"Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body (PubMed:7504305, PubMed:7531687, PubMed:7544004, PubMed:7682706). In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such PTGS2/COX2 (By similarity). As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM (PubMed:25417112). Involved in inflammation, enhances the synthesis of pro-inflammatory mediators such as IL6 and IL8 (PubMed:19688109)","subcellular_location":"Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/P35228/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NOS2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NOS2","total_profiled":1310},"omim":[{"mim_id":"611162","title":"MALARIA, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/611162"},{"mim_id":"608228","title":"NANOS C2HC-TYPE ZINC FINGER 2; NANOS2","url":"https://www.omim.org/entry/608228"},{"mim_id":"608212","title":"IMMUNITY-RELATED GTPase M; IRGM","url":"https://www.omim.org/entry/608212"},{"mim_id":"605692","title":"TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 7; TRPM7","url":"https://www.omim.org/entry/605692"},{"mim_id":"604702","title":"HMG BOX DOMAIN-CONTAINING 4; HMGXB4","url":"https://www.omim.org/entry/604702"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":19.6},{"tissue":"lymphoid tissue","ntpm":13.8}],"url":"https://www.proteinatlas.org/search/NOS2"},"hgnc":{"alias_symbol":["iNOS","NOS","HEP-NOS"],"prev_symbol":["NOS2A"]},"alphafold":{"accession":"P35228","domains":[{"cath_id":"3.40.50.360","chopping":"521-699","consensus_level":"high","plddt":85.7696,"start":521,"end":699},{"cath_id":"1.20.990.10","chopping":"707-713_780-809_824-899","consensus_level":"high","plddt":90.5057,"start":707,"end":899},{"cath_id":"2.40.30.10","chopping":"733-778_906-965","consensus_level":"medium","plddt":90.9233,"start":733,"end":965},{"cath_id":"3.40.50.80","chopping":"971-1133","consensus_level":"high","plddt":90.6331,"start":971,"end":1133}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P35228","model_url":"https://alphafold.ebi.ac.uk/files/AF-P35228-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P35228-F1-predicted_aligned_error_v6.png","plddt_mean":85.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NOS2","jax_strain_url":"https://www.jax.org/strain/search?query=NOS2"},"sequence":{"accession":"P35228","fasta_url":"https://rest.uniprot.org/uniprotkb/P35228.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P35228/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P35228"}},"corpus_meta":[{"pmid":"9657518","id":"PMC_9657518","title":"Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III).","date":"1998","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9657518","citation_count":492,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26335399","id":"PMC_26335399","title":"The dual role of iNOS in cancer.","date":"2015","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/26335399","citation_count":394,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8577713","id":"PMC_8577713","title":"Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8577713","citation_count":347,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9486966","id":"PMC_9486966","title":"Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer.","date":"1998","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9486966","citation_count":346,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15914026","id":"PMC_15914026","title":"Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin.","date":"2005","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/15914026","citation_count":315,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30501075","id":"PMC_30501075","title":"Regulation of iNOS on Immune Cells and Its Role in Diseases.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30501075","citation_count":304,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17956292","id":"PMC_17956292","title":"Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase.","date":"2007","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/17956292","citation_count":249,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14664901","id":"PMC_14664901","title":"The DDAH/ADMA/NOS pathway.","date":"2003","source":"Atherosclerosis. Supplements","url":"https://pubmed.ncbi.nlm.nih.gov/14664901","citation_count":245,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31382355","id":"PMC_31382355","title":"Endothelial Dysfunction: Is There a Hyperglycemia-Induced Imbalance of NOX and NOS?","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31382355","citation_count":241,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31672462","id":"PMC_31672462","title":"iNOS as a metabolic enzyme under stress conditions.","date":"2019","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31672462","citation_count":154,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11393255","id":"PMC_11393255","title":"iNOS and nitrotyrosine expression after spinal cord injury.","date":"2001","source":"Journal of neurotrauma","url":"https://pubmed.ncbi.nlm.nih.gov/11393255","citation_count":149,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24733928","id":"PMC_24733928","title":"Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24733928","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30341769","id":"PMC_30341769","title":"Endothelial NOS: perspective and recent developments.","date":"2018","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30341769","citation_count":140,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10593859","id":"PMC_10593859","title":"Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP.","date":"1999","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/10593859","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32017079","id":"PMC_32017079","title":"Role of iNOS in osteoarthritis: Pathological and therapeutic aspects.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32017079","citation_count":131,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14510775","id":"PMC_14510775","title":"From molecules to mammals: what's NOS got to do with it?","date":"2003","source":"Acta physiologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/14510775","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10847627","id":"PMC_10847627","title":"Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene.","date":"2000","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/10847627","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10506586","id":"PMC_10506586","title":"Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy.","date":"1999","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/10506586","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16908860","id":"PMC_16908860","title":"NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16908860","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10072717","id":"PMC_10072717","title":"Expression of cardiac cytokines and inducible form of nitric oxide synthase (NOS2) in Trypanosoma cruzi-infected mice.","date":"1999","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/10072717","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10322315","id":"PMC_10322315","title":"Brain iNOS: current understanding and clinical implications.","date":"1999","source":"Molecular medicine today","url":"https://pubmed.ncbi.nlm.nih.gov/10322315","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26117324","id":"PMC_26117324","title":"Signaling and stress: The redox landscape in NOS2 biology.","date":"2015","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26117324","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10484439","id":"PMC_10484439","title":"Codistribution of NOS and caveolin throughout peripheral vasculature and skeletal muscle of hamsters.","date":"1999","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10484439","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17395508","id":"PMC_17395508","title":"Differences in inflammatory pain in nNOS-, iNOS- and eNOS-deficient mice.","date":"2007","source":"European journal of pain (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17395508","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12138131","id":"PMC_12138131","title":"Histone deacetylases augment cytokine induction of the iNOS gene.","date":"2002","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/12138131","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19096157","id":"PMC_19096157","title":"The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP.","date":"2008","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/19096157","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11490353","id":"PMC_11490353","title":"The role of iNOS in wound healing.","date":"2001","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/11490353","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10710369","id":"PMC_10710369","title":"Functional expression of NOS 1 in vascular smooth muscle.","date":"2000","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10710369","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16499902","id":"PMC_16499902","title":"Translational repression restricts expression of the C. elegans Nanos homolog NOS-2 to the embryonic germline.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16499902","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27246103","id":"PMC_27246103","title":"The Sur1-Trpm4 channel regulates NOS2 transcription in TLR4-activated microglia.","date":"2016","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/27246103","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21832306","id":"PMC_21832306","title":"Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia.","date":"2011","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/21832306","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10198298","id":"PMC_10198298","title":"Mechanism of adipose tissue iNOS induction in endotoxemia.","date":"1999","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10198298","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10350565","id":"PMC_10350565","title":"Expression of inducible nitric oxide synthase (iNOS/NOS II) in the cochlea of guinea pigs after intratympanical endotoxin-treatment.","date":"1999","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10350565","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28506076","id":"PMC_28506076","title":"NOS2 as an Emergent Player in Progression of Cancer.","date":"2017","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/28506076","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25170849","id":"PMC_25170849","title":"Expression of inducible nitric oxide synthase (iNOS) in microglia of the developing quail retina.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25170849","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11309233","id":"PMC_11309233","title":"Inducible nitric oxide synthase (iNOS) activity promotes ischaemic skin flap survival.","date":"2001","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11309233","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19501636","id":"PMC_19501636","title":"Comparative analysis of zebrafish nos2a and nos2b genes.","date":"2009","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/19501636","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16787174","id":"PMC_16787174","title":"Nitric oxide synthase (NOS) as therapeutic target for asthma and chronic obstructive pulmonary disease.","date":"2006","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/16787174","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26097999","id":"PMC_26097999","title":"The role of iNOS in cholesterol-induced liver fibrosis.","date":"2015","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26097999","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22618808","id":"PMC_22618808","title":"NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22618808","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12618316","id":"PMC_12618316","title":"Altered expression of inducible nitric oxide synthase (iNOS) in the cochlea.","date":"2003","source":"Hearing research","url":"https://pubmed.ncbi.nlm.nih.gov/12618316","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23416151","id":"PMC_23416151","title":"Microglial CD14 activated by iNOS contributes to neuroinflammation in cerebral ischemia.","date":"2013","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/23416151","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15174013","id":"PMC_15174013","title":"Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis.","date":"2004","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15174013","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35978195","id":"PMC_35978195","title":"LACC1 bridges NOS2 and polyamine metabolism in inflammatory macrophages.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35978195","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12552317","id":"PMC_12552317","title":"Nucleotide and haplotypic diversity of the NOS2A promoter region and its relationship to cerebral malaria.","date":"2003","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12552317","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21039732","id":"PMC_21039732","title":"Inducible nitric oxide synthase (iNOS) gene polymorphism and disease prevalence.","date":"2010","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21039732","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23922688","id":"PMC_23922688","title":"A scallop nitric oxide synthase (NOS) with structure similar to neuronal NOS and its involvement in the immune defense.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23922688","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9635249","id":"PMC_9635249","title":"Differential expression of arginase and iNOS in the lung in sepsis.","date":"1998","source":"Experimental lung research","url":"https://pubmed.ncbi.nlm.nih.gov/9635249","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12169580","id":"PMC_12169580","title":"Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells.","date":"2002","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12169580","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22826608","id":"PMC_22826608","title":"Inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are important mediators of reflux-induced cell signalling in esophageal cells.","date":"2012","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22826608","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34027652","id":"PMC_34027652","title":"Regulation of NOS expression in vascular diseases.","date":"2021","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/34027652","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9811327","id":"PMC_9811327","title":"NOS2 mediates opposing effects in models of acute and chronic cardiac rejection: insights from NOS2-knockout mice.","date":"1998","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9811327","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17955236","id":"PMC_17955236","title":"Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility.","date":"2007","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/17955236","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12097137","id":"PMC_12097137","title":"Inducible nitric oxide synthase (NOS2) expressed in septic patients is nitrated on selected tyrosine residues: implications for enzymic activity.","date":"2002","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12097137","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24858340","id":"PMC_24858340","title":"Induction of inducible nitric oxide synthase (iNOS) expression by oxLDL inhibits macrophage derived foam cell migration.","date":"2014","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/24858340","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17561811","id":"PMC_17561811","title":"Inhibition of spinal constitutive NOS-2 by 1400W attenuates tissue injury and inflammation-induced hyperalgesia and spinal p38 activation.","date":"2007","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17561811","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35652349","id":"PMC_35652349","title":"Brown Adipocyte ADRB3 Mediates Cardioprotection via Suppressing Exosomal iNOS.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/35652349","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18820242","id":"PMC_18820242","title":"Novel noncoding antisense RNA transcribed from human anti-NOS2A locus is differentially regulated during neuronal differentiation of embryonic stem cells.","date":"2008","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18820242","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14551604","id":"PMC_14551604","title":"Haplotypic relationship between SNP and microsatellite markers at the NOS2A locus in two populations.","date":"2003","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/14551604","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22715033","id":"PMC_22715033","title":"NOS-2 signaling and cancer therapy.","date":"2012","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/22715033","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30227679","id":"PMC_30227679","title":"Involvement of NOS2 Activity on Human Glioma Cell Growth, Clonogenic Potential, and Neurosphere Generation.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30227679","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10516639","id":"PMC_10516639","title":"Inhibition of NOS-2 expression in macrophages through the inactivation of NF-kappaB by andalusol.","date":"1999","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10516639","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31995689","id":"PMC_31995689","title":"Fatal Cytomegalovirus Infection in an Adult with Inherited NOS2 Deficiency.","date":"2020","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31995689","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15894526","id":"PMC_15894526","title":"Deletion of iNOS gene impairs mouse fracture healing.","date":"2005","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/15894526","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29774240","id":"PMC_29774240","title":"Mannan-induced Nos2 in macrophages enhances IL-17-driven psoriatic arthritis by innate lymphocytes.","date":"2018","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/29774240","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27623813","id":"PMC_27623813","title":"Transdifferentiation Requires iNOS Activation: Role of RING1A S-Nitrosylation.","date":"2016","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/27623813","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40389042","id":"PMC_40389042","title":"Inducible nitric oxide synthase (iNOS): More than an inducible enzyme? Rethinking the classification of NOS isoforms.","date":"2025","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/40389042","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16404814","id":"PMC_16404814","title":"The DDAH-ADMA-NOS pathway.","date":"2005","source":"Therapeutic drug monitoring","url":"https://pubmed.ncbi.nlm.nih.gov/16404814","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30152521","id":"PMC_30152521","title":"Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective.","date":"2018","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30152521","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26526764","id":"PMC_26526764","title":"Role of NOS2 in pulmonary injury and repair in response to bleomycin.","date":"2015","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26526764","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16771678","id":"PMC_16771678","title":"Effects of noradrenaline on neuronal NOS2 expression and viability.","date":"2006","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/16771678","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30927077","id":"PMC_30927077","title":"Increased inducible nitric oxide synthase (iNOS) expression in human myocardial infarction.","date":"2019","source":"International journal of legal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30927077","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19329460","id":"PMC_19329460","title":"Orthodontic force stimulates eNOS and iNOS in rat osteocytes.","date":"2009","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/19329460","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32554491","id":"PMC_32554491","title":"DNA-based fluorescent probes of NOS2 activity in live brains.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32554491","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10374872","id":"PMC_10374872","title":"Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes.","date":"1999","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/10374872","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17987386","id":"PMC_17987386","title":"iNOS expression in oral and gastrointestinal tract mucosa.","date":"2008","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17987386","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12076971","id":"PMC_12076971","title":"Thioredoxin-related regulation of NO/NOS activities.","date":"2002","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12076971","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31173276","id":"PMC_31173276","title":"The modulation of endometriosis by lncRNA MALAT1 via NF-κB/iNOS.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31173276","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25003233","id":"PMC_25003233","title":"mNos2 deletion and human NOS2 replacement in Alzheimer disease models.","date":"2014","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25003233","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16574921","id":"PMC_16574921","title":"Association analysis of common variants of ELN, NOS2A, APOE and ACE2 to intracranial aneurysm.","date":"2006","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/16574921","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15565661","id":"PMC_15565661","title":"PGE1-induced NO reduces apoptosis by D-galactosamine through attenuation of NF-kappaB and NOS-2 expression in rat hepatocytes.","date":"2004","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15565661","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20580828","id":"PMC_20580828","title":"An inducible nitric oxide synthase (NOS) is expressed in hemocytes of the spiny lobster Panulirus argus: cloning, characterization and expression analysis.","date":"2010","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20580828","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11208553","id":"PMC_11208553","title":"Endothelial E- and P-selectin expression in iNOS- deficient mice exposed to polymicrobial sepsis.","date":"2001","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11208553","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22174044","id":"PMC_22174044","title":"Gene deletion of nos2 protects against manganese-induced neurological dysfunction in juvenile mice.","date":"2011","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/22174044","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18675339","id":"PMC_18675339","title":"Ascorbate sustains neutrophil NOS expression, catalysis, and oxidative burst.","date":"2008","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18675339","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23438482","id":"PMC_23438482","title":"Proteomic analysis of the NOS2 interactome in human airway epithelial cells.","date":"2013","source":"Nitric oxide : biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23438482","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35584114","id":"PMC_35584114","title":"NOS2 and S-nitrosothiol signaling induces DNA hypomethylation and LINE-1 retrotransposon expression.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35584114","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16103686","id":"PMC_16103686","title":"NOS 1 is required for allergen-induced expression of NOS 2 in mice.","date":"2005","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16103686","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9842423","id":"PMC_9842423","title":"Nitric oxide synthase I (NOS I) is a costameric enzyme in rat skeletal muscle.","date":"1998","source":"Acta histochemica","url":"https://pubmed.ncbi.nlm.nih.gov/9842423","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27397579","id":"PMC_27397579","title":"Macrophage NOS2 in Tumor Leukocytes.","date":"2016","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/27397579","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10674474","id":"PMC_10674474","title":"The CCTTT polymorphism in the NOS2A gene is associated with dementia with Lewy bodies.","date":"2000","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/10674474","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11216878","id":"PMC_11216878","title":"Differential expression and regulation of inducible nitric oxide synthase (iNOS) mRNA in human trophoblasts in vitro.","date":"2001","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/11216878","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16966449","id":"PMC_16966449","title":"Coexpression of NRAMP1, iNOS, and nitrotyrosine in bovine tuberculosis.","date":"2006","source":"Veterinary pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16966449","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23474170","id":"PMC_23474170","title":"PEX7 and EBP50 target iNOS to the peroxisome in hepatocytes.","date":"2013","source":"Nitric oxide : biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23474170","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18341205","id":"PMC_18341205","title":"Inducible nitric oxide synthase (iNOS): role in asthma pathogenesis.","date":"2007","source":"Indian journal of biochemistry & biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/18341205","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23072468","id":"PMC_23072468","title":"On the selectivity of neuronal NOS inhibitors.","date":"2013","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23072468","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11922988","id":"PMC_11922988","title":"The avian griseum tectale: cytoarchitecture, NOS expression and neurogenesis.","date":"2002","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/11922988","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27402673","id":"PMC_27402673","title":"Transcriptional activation and translocation of ancient NOS during immune response.","date":"2016","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/27402673","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11509447","id":"PMC_11509447","title":"Nitric oxide synthase (NOS2) mutation in Dahl/Rapp rats decreases enzyme stability.","date":"2001","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/11509447","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30420450","id":"PMC_30420450","title":"Interplay of Nitric Oxide Synthase (NOS) and SrrAB in Modulation of Staphylococcus aureus Metabolism and Virulence.","date":"2019","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30420450","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23128233","id":"PMC_23128233","title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23128233","citation_count":3725,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7682706","id":"PMC_7682706","title":"Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7682706","citation_count":828,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7524082","id":"PMC_7524082","title":"Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7524082","citation_count":507,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7528106","id":"PMC_7528106","title":"Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation.","date":"1994","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7528106","citation_count":451,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20438856","id":"PMC_20438856","title":"Regulation of the expression of inducible nitric oxide synthase.","date":"2010","source":"Nitric oxide : biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20438856","citation_count":427,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8653828","id":"PMC_8653828","title":"Expression of inducible nitric oxide synthase in human heart failure.","date":"1996","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/8653828","citation_count":419,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7544004","id":"PMC_7544004","title":"Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7544004","citation_count":416,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8383325","id":"PMC_8383325","title":"Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8383325","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10074942","id":"PMC_10074942","title":"Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation.","date":"1999","source":"Nature structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/10074942","citation_count":387,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28319085","id":"PMC_28319085","title":"Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.","date":"2017","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/28319085","citation_count":378,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8943206","id":"PMC_8943206","title":"Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8943206","citation_count":360,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7531613","id":"PMC_7531613","title":"Expression of nitric oxide synthase in human central nervous system tumors.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7531613","citation_count":337,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7509810","id":"PMC_7509810","title":"Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7509810","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7504305","id":"PMC_7504305","title":"Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7504305","citation_count":291,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20953189","id":"PMC_20953189","title":"Genome-wide association analysis identifies three psoriasis susceptibility loci.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20953189","citation_count":270,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21729780","id":"PMC_21729780","title":"Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.","date":"2011","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21729780","citation_count":263,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10450191","id":"PMC_10450191","title":"Nitric oxide: discovery and impact on clinical medicine.","date":"1999","source":"Journal of the Royal Society of Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10450191","citation_count":252,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7544003","id":"PMC_7544003","title":"The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 surface antigen.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7544003","citation_count":235,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17703412","id":"PMC_17703412","title":"Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes.","date":"2007","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17703412","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7692964","id":"PMC_7692964","title":"Purification and cDNA sequence of an inducible nitric oxide synthase from a human tumor cell line.","date":"1993","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7692964","citation_count":214,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18849972","id":"PMC_18849972","title":"Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase.","date":"2008","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/18849972","citation_count":211,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20978357","id":"PMC_20978357","title":"Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.","date":"2010","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20978357","citation_count":210,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16352737","id":"PMC_16352737","title":"A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis.","date":"2005","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16352737","citation_count":201,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11050162","id":"PMC_11050162","title":"Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11050162","citation_count":194,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17720813","id":"PMC_17720813","title":"NOS2 regulation of NF-kappaB by S-nitrosylation of p65.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17720813","citation_count":194,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19688109","id":"PMC_19688109","title":"Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage--mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production.","date":"2009","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/19688109","citation_count":194,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10409685","id":"PMC_10409685","title":"Crystal structures of zinc-free and -bound heme domain of human inducible nitric-oxide synthase. Implications for dimer stability and comparison with endothelial nitric-oxide synthase.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10409685","citation_count":193,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46600,"output_tokens":5934,"usd":0.114405},"stage2":{"model":"claude-opus-4-6","input_tokens":9559,"output_tokens":3701,"usd":0.21048},"total_usd":0.773519,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":59584,"output_tokens":8304,"usd":0.151656},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12432,"output_tokens":5433,"usd":0.296978}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"Human NOS2 gene transcription is activated by cytokines (TNF-α, IL-1β, IFN-γ), with multiple cytokine-responsive enhancer elements located at -3.8 to -5.8 kb, -5.8 to -7.0 kb, and -7.0 to -16 kb upstream of the transcription start site — in marked contrast to the murine macrophage NOS2 promoter which requires only ~1 kb of 5'-flanking sequence.\",\n      \"method\": \"Nuclear run-on transcription assay, luciferase reporter transfection with deletion constructs of the NOS2 promoter in human liver epithelial cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct promoter dissection with multiple deletion constructs and nuclear run-on validation\",\n      \"pmids\": [\"8577713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"iNOS (NOS2) is required for normal wound closure; iNOS-knockout mice show 31% delayed wound closure, and a single topical application of an adenoviral human iNOS cDNA vector completely reverses this defect.\",\n      \"method\": \"iNOS knockout mouse model, iNOS inhibitor infusion, adenoviral gene transfer rescue, RT-PCR for iNOS mRNA expression\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + pharmacological inhibition + gene-transfer rescue with defined phenotypic readout, replicated across multiple approaches in one study\",\n      \"pmids\": [\"9486966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"NOS2 promotes acute cardiac allograft rejection (NOS2-deficient recipients show reduced inflammatory infiltrates and myocyte damage) but protects against chronic rejection (NOS2-deficient recipients show more parenchymal destruction and decreased ventricular contractility), demonstrating opposing context-dependent roles.\",\n      \"method\": \"NOS2 knockout mice as cardiac transplant recipients, histological scoring, RT-PCR and immunohistochemistry for NOS2, palpation scoring of contractility\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype in two distinct models\",\n      \"pmids\": [\"9811327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Induction of iNOS in adipose tissue by endotoxemia (LPS) requires a concerted action of TNF-α, IFN-γ, and LPS; none of these stimuli alone is sufficient to induce iNOS activity in 3T3-L1 adipocytes in vitro.\",\n      \"method\": \"In vivo rat LPS model, cultured 3T3-L1 adipocytes treated with individual and combined cytokines/LPS, iNOS mRNA/protein assay, NOS activity assay\",\n      \"journal\": \"The American journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo + in vitro complementary approaches with orthogonal readouts\",\n      \"pmids\": [\"10198298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The (CCTTT)n pentanucleotide repeat in the NOS2A promoter differentially regulates transcription; the 14-repeat allele confers greater IL-1β-induced transcription in transfected cells and is less suppressed by high glucose, linking promoter polymorphism to functional transcriptional output.\",\n      \"method\": \"Luciferase reporter gene assay with various (CCTTT)n repeat constructs transfected into colonic carcinoma cells, stimulated with IL-1β ± 25 mM glucose\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro transcription assay, single lab\",\n      \"pmids\": [\"10506586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"iNOS-deficient fibroblasts show impaired wound-healing properties: reduced proliferation, decreased collagen synthesis, and slower collagen lattice contraction; exogenous NO donor (SNAP) restores collagen synthesis to normal levels, establishing iNOS-derived NO as mechanistically required for these processes.\",\n      \"method\": \"iNOS knockout mouse dermal fibroblast explant cultures, [3H]-thymidine and [3H]-proline incorporation assays, fibroblast-populated collagen lattice contraction assay, NO donor rescue\",\n      \"journal\": \"Surgery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + pharmacological rescue with multiple orthogonal functional readouts\",\n      \"pmids\": [\"11490353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NOS2 (iNOS) promotes sepsis-induced upregulation of E- and P-selectin in systemic microvasculature; iNOS-/- mice subjected to cecal ligation and puncture show substantially reduced E- and P-selectin expression in peritoneal organs.\",\n      \"method\": \"iNOS knockout mice in cecal ligation and perforation model, tissue myeloperoxidase activity, E/P-selectin expression assessed by immunohistochemistry/ELISA\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined molecular readout, single lab\",\n      \"pmids\": [\"11208553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"S714P mutation in rat NOS2 reduces enzyme protein stability (decreased protein half-life by metabolic labeling) without altering mRNA levels, leading to diminished nitrite production; proteasomal degradation is implicated as the posttranslational mechanism.\",\n      \"method\": \"Transient transfection of COS-7 cells with wild-type and S714P/S714A NOS2 mutants, immunoblot, metabolic labeling, nitrite assay, mRNA analysis\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — site-directed mutagenesis + metabolic labeling + functional assay in transfected cells\",\n      \"pmids\": [\"11509447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"HDAC2 physically interacts with NF-κB p65 and is recruited to the NOS2 promoter; HDAC inhibition with trichostatin A suppresses cytokine-induced NOS2 transcription and NO production, while HDAC isoform overexpression enhances it, establishing that NOS2 transcription is positively regulated by HDACs via NF-κB.\",\n      \"method\": \"Co-immunoprecipitation of HDAC2 with NF-κB p65 from nuclear extracts, GST pulldown with p65 fusion protein, transient transfection NOS2 promoter-luciferase assays, Griess reaction for NO, trichostatin A inhibitor studies\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — Co-IP + GST pulldown + promoter assays + functional NO measurement, multiple orthogonal methods\",\n      \"pmids\": [\"12138131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Human NOS2 tyrosine residues can be nitrated by peroxynitrite in vitro, leading to decreased enzymatic activity; NOS2 expressed in skeletal muscle of septic patients is nitrated on selective tyrosine residues in a canonical sequence, establishing tyrosine nitration as an endogenous mechanism of NOS2 activity modulation.\",\n      \"method\": \"In vitro peroxynitrite treatment of purified NOS2, Western blot and mass spectrometry for nitrotyrosine on human patient tissue NOS2\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical assay + human tissue validation with MS identification\",\n      \"pmids\": [\"12097137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Rho GTPase signaling through ROCK suppresses NOS2 mRNA and protein levels downstream of promoter activity in human alveolar epithelial cells, while statin-mediated HMG-CoA reductase inhibition increases NOS2 promoter activity through a prenylation-dependent mechanism independent of Rho GTPase.\",\n      \"method\": \"ROCK inhibitor (Y-27632), statin treatment, geranylgeranyl pyrophosphate rescue, NOS2 promoter-luciferase assays, RT-PCR, Western blot in human alveolar epithelial cells\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection with multiple inhibitors and orthogonal readouts, single lab\",\n      \"pmids\": [\"12169580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"iNOS gene deletion impairs mouse fracture healing, reducing energy absorption of healing bone by 30–70%; this is reversed by adenoviral delivery of iNOS cDNA to the fracture site, establishing iNOS-derived NO as mechanistically required for fracture repair.\",\n      \"method\": \"iNOS knockout mice, femoral osteotomy model, torsional biomechanical testing (INSTRON), adenoviral iNOS gene transfer rescue\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + gene-transfer rescue with quantitative biomechanical phenotype\",\n      \"pmids\": [\"15894526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Genetic deletion of NOS2 in an amyloid precursor protein (APP) Swedish mutant mouse model results in pathological tau hyperphosphorylation, tau redistribution to somatodendritic compartments, increased insoluble Aβ, neuronal degeneration, and caspase-3 activation — establishing that NO from NOS2 acts at a junction between Aβ peptides, caspase activation, and tau aggregation.\",\n      \"method\": \"NOS2 knockout × APP Swedish mutant bigenic mice, immunohistochemistry, Western blot for phospho-tau, Aβ ELISA, caspase-3 activity assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (double KO/transgenic) with multiple orthogonal molecular pathology readouts\",\n      \"pmids\": [\"16908860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"iNOS localizes to peroxisomes in hepatocytes through interaction with the peroxisomal import protein PEX7 and the scaffold protein EBP50; siRNA knockdown of PEX7 reduces iNOS colocalization with the peroxisomal marker PMP70, and EBP50 associates with peroxisomes in a PEX5/PEX7-dependent manner.\",\n      \"method\": \"siRNA knockdown of PEX7 and EBP50, confocal microscopy, immunoelectron microscopy, MALDI-MS proteomic identification of EBP50 as NOS2-interacting protein, LPS-treated mice\",\n      \"journal\": \"Nitric oxide : biology and chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown + co-localization imaging + MS identification + in vivo validation\",\n      \"pmids\": [\"23474170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NOS2 interactome in human airway epithelial cells includes allosteric activators and ubiquitin-proteasome system components; FBXO45 is identified as a novel direct NOS2-interacting ubiquitin ligase scaffolding protein that requires Asn27 in the (23)DINNN(27) motif of NOS2 for interaction and recruits a distinct E3 ligase complex containing MYCBP2 and SKP1.\",\n      \"method\": \"Flag-tagged catalytically-inactive NOS2 overexpression, co-immunoprecipitation, SILAC quantitative mass spectrometry, NOS2 ubiquitination assay, cytokine stimulation in A549 cells\",\n      \"journal\": \"Nitric oxide : biology and chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — quantitative MS interactome + interaction domain mapping + ubiquitination functional assay\",\n      \"pmids\": [\"23438482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NOS2 drives breast cancer metastasis and chemoresistance: NOS2 is upregulated by hypoxia, serum withdrawal, IFN-γ, and exogenous NO in a feed-forward manner; NOS2 inhibition in MDA-MB-231 cells suppresses S100A8, IL-6, IL-8, TIMP-1 levels, reduces cellular migration and Taxol resistance, and significantly suppresses xenograft tumor growth and brain metastasis.\",\n      \"method\": \"NOS2 pharmacological inhibition in breast cancer cell lines, MDA-MB-231 xenograft mouse model, fat pad-to-brain metastasis assay, cytokine/marker quantification\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro + in vivo genetic/pharmacological studies with multiple molecular and functional readouts\",\n      \"pmids\": [\"24733928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Sur1-Trpm4 channel activity in TLR4-activated microglia regulates NOS2 expression by modulating intracellular Ca2+ and Ca2+/calmodulin-dependent kinase II phosphorylation of calcineurin, which controls NFAT nuclear translocation and subsequent NOS2 transcription; inhibition or silencing of Sur1-Trpm4 reduces NFAT nuclear translocation and NOS2 upregulation despite increased cytoplasmic Ca2+.\",\n      \"method\": \"Pharmacological inhibition (glibenclamide, 9-phenanthrol), siRNA knockdown of Abcc8/Trpm4, patch clamp, Ca2+ imaging, chromatin immunoprecipitation for NFAT at NOS2 promoter, qPCR, Griess assay, immunoblot\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP + Ca2+ imaging + electrophysiology + genetic KO + pharmacological inhibition, multiple orthogonal methods\",\n      \"pmids\": [\"27246103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"During transdifferentiation of fibroblasts to endothelial cells, NF-κB activation induces iNOS nuclear translocation; nuclear iNOS binds and S-nitrosylates the epigenetic repressor RING1A at Cys398, reducing RING1A chromatin binding and global H3K27me3 levels to enable epigenetic reprogramming. A C398A RING1A mutant lacking the nitrosylation site nearly abolishes transdifferentiation.\",\n      \"method\": \"iNOS KO murine embryonic fibroblasts, siRNA knockdown, iNOS overexpression rescue, Co-IP, mass spectrometry of S-nitrosylation site, immunostaining for nuclear iNOS localization, H3K27me3 ChIP/global levels, RING1A C398A mutant overexpression\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — MS identification of nitrosylation site + mutagenesis + genetic KO/rescue + ChIP, multiple orthogonal methods in single study\",\n      \"pmids\": [\"27623813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In a mannan-induced psoriatic arthritis mouse model, Nos2-derived NO from macrophages promotes IL-1α release from skin macrophages, which in turn drives IL-17 production by innate lymphoid cells to cause arthritis; Nos2 deletion or pharmacological NOS inhibition suppresses disease, and NOS2 expression is upregulated in PsA patient monocyte subsets.\",\n      \"method\": \"Nos2 knockout mice, NOS inhibitor (L-NAME) treatment, cytokine measurement, mannan-induced psoriasis/arthritis (MIP) model, monocyte analysis from human PsA patients\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + pharmacological inhibition + epistasis with IL-1α pathway + human patient data\",\n      \"pmids\": [\"29774240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Inherited homozygous loss-of-function frameshift mutation in human NOS2 (producing a truncated, NO-nonproducing protein) causes susceptibility to fatal CMV infection, establishing NOS2-derived NO as specifically required for human immune defense against CMV.\",\n      \"method\": \"Whole-exome sequencing, functional testing of mutant NOS2 alleles for NO production, clinical immunological characterization of patient\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — human genetic loss-of-function with biochemical validation of truncated non-functional protein\",\n      \"pmids\": [\"31995689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LACC1 enzymatically converts L-citrulline (the NOS2 byproduct) to L-ornithine and isocyanic acid, bridging NOS2-mediated NO production to the downstream polyamine synthesis pathway via ornithine decarboxylase 1 (ODC1) in inflammatory macrophages; LACC1 phenotypes in Salmonella infection require upstream NOS2 and downstream ODC1, and chemical complementation with L-ornithine restores wild-type function in Lacc1-/- macrophages.\",\n      \"method\": \"Biochemical enzymatic reconstitution of LACC1 activity, Lacc1/Nos2/Odc1 knockout mouse models, bone marrow-derived macrophages infected with Salmonella enterica, L-ornithine chemical complementation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution of novel enzymatic activity + genetic epistasis across three KO models + chemical rescue\",\n      \"pmids\": [\"35978195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NOS2 expression and associated NO signaling induces degradation of DNMT1 protein via an NO/p38-MAPK/KAT5-dependent mechanism, causing DNA hypomethylation, LINE-1 retrotransposon hypomethylation and expression, DNA damage, and epithelial cellular transformation.\",\n      \"method\": \"NOS2-expressing human cell lines, DNMT1 protein stability assays, p38-MAPK inhibition, KAT5 involvement, bisulfite sequencing for LINE-1 methylation, transformation assays, correlation with human breast tumor data\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic pathway dissection with pharmacological inhibitors + epigenomic readouts + transformation assay\",\n      \"pmids\": [\"35584114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Brown adipocyte ADRB3 activation suppresses iNOS packaging into exosomes; brown adipocyte-derived exosomes containing iNOS exacerbate cardiac fibroblast dysfunction and Ang II-induced cardiac remodeling, and iNOS knockdown in brown adipocytes reverses the pro-fibrotic effect of ADRB3 antagonist-conditioned exosomes.\",\n      \"method\": \"Brown adipocyte-specific ADRB3 KO mice, Ang II infusion cardiac model, in vitro exosome transfer to cardiac fibroblasts, iNOS siRNA knockdown in brown adipocytes, exosome inhibitor treatment, Western blot for iNOS in exosomes\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + siRNA rescue + exosome transfer experiments with defined cardiac phenotype\",\n      \"pmids\": [\"35652349\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NOS2 (iNOS) is a transcriptionally regulated enzyme induced by cytokines and pathogen-associated signals via NF-κB, NFAT, and other transcription factors; it produces sustained high-level NO from L-arginine (yielding L-citrulline as byproduct), with the citrulline channeled to polyamine synthesis via LACC1/ODC1; NOS2 activity is modulated post-translationally by peroxynitrite-mediated tyrosine nitration and proteasomal degradation (regulated by FBXO45/MYCBP2 E3 ligase via the DINNN motif), and by peroxisomal targeting through PEX7/EBP50; nuclear iNOS can directly S-nitrosylate the epigenetic repressor RING1A to relieve H3K27me3 repression, and can also cause DNMT1 degradation via p38-MAPK/KAT5 to drive DNA hypomethylation; in immune contexts, NOS2-derived NO mediates host defense against pathogens (including CMV in humans), drives macrophage-dependent IL-1α/IL-17 inflammatory signaling, and promotes or restrains tumor progression depending on concentration and cellular context.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"Molecular cloning of human inducible NOS (NOS2/iNOS) from hepatocytes revealed an 80% amino acid sequence homology to murine macrophage NOS, with recognition sites for FMN, FAD, and NADPH and a consensus calmodulin binding site; unlike the murine macrophage isoform, the human hepatocyte enzyme showed Ca2+ dependence when expressed in 293 kidney cells.\",\n      \"method\": \"cDNA cloning, heterologous expression in 293 cells, enzymatic assay with Ca2+ chelation and calmodulin antagonist\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning paper with direct enzymatic characterization and functional validation in transfected cells\",\n      \"pmids\": [\"7682706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Cloning of inducible NOS from human chondrocytes confirmed a single human iNOS isoform (1153 amino acids, ~131 kDa); CHO cells transfected with this cDNA expressed NOS activity inhibitable by L-arginine analogues, establishing the catalytic competence of the cloned sequence.\",\n      \"method\": \"cDNA cloning, CHO cell transfection, NOS activity inhibition assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in heterologous cells with inhibitor validation; replicated across multiple human cell types\",\n      \"pmids\": [\"7504305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Purification and cDNA sequencing of cytokine-induced NOS from a human colorectal adenocarcinoma cell line (DLD-1) confirmed that purified human iNOS shares with murine macrophage iNOS a lack of dependence on exogenous calcium and calmodulin for activity, distinguishing it from brain and endothelial NOS isoforms.\",\n      \"method\": \"Enzyme purification, calmodulin-independent activity assay, cDNA sequencing\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified enzyme with direct biochemical characterization\",\n      \"pmids\": [\"7692964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"NOS2-derived nitric oxide mediates cytokine-induced inhibition of glucose-stimulated insulin secretion by human islets of Langerhans; this was demonstrated by prevention of both cGMP accumulation and nitrite production, and restoration of insulin secretion, by the NOS inhibitor L-NMMA.\",\n      \"method\": \"Human islet culture, cytokine stimulation, L-NMMA inhibition, nitrite assay, cGMP measurement, insulin secretion assay, EPR spectroscopy\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods establishing mechanistic link between iNOS-derived NO and beta-cell dysfunction\",\n      \"pmids\": [\"8383325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The human NOS2 gene is approximately 37 kb in length, consists of 26 exons and 25 introns, and is located on chromosome 17 at position 17cen-q11.2; primer extension mapped the transcriptional initiation site 30 bp downstream of a TATA sequence, and cytokine-inducible promoter elements reside within a ~400 bp 5'-flanking region.\",\n      \"method\": \"Genomic library screening, exon-intron mapping, primer extension, FISH, somatic cell hybrid PCR panel\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — comprehensive structural genomic characterization with independent chromosomal localization methods\",\n      \"pmids\": [\"7509810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Constitutive NOS2 (iNOS) expression occurs in Epstein-Barr virus-transformed human B lymphocytes; NOS2-derived NO maintains EBV latency by down-regulating expression of the immediate-early EBV transactivator Zta and also inhibits apoptosis in B lymphocyte cell lines through cGMP-independent, redox/sulfhydryl-dependent mechanisms.\",\n      \"method\": \"RT-PCR, NOS activity assay, EBV reactivation assay, apoptosis assay, cGMP-independent pathway analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional readouts linking constitutive iNOS activity to EBV latency and cell survival\",\n      \"pmids\": [\"7528106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Continuous, constitutive expression of NOS2 (iNOS) in normal human airway epithelial cells in vivo was demonstrated by molecular cloning; expression was dependent on the in vivo airway environment, was abolished upon cell removal, and was decreased by inhaled corticosteroids and β-adrenergic agonists.\",\n      \"method\": \"Molecular cloning, in situ hybridization, NOS activity quantitation in epithelial cell lysates, in vivo pharmacological inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct cloning from airway tissue with quantitative activity measurement and in vivo pharmacological modulation\",\n      \"pmids\": [\"7544004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Transcriptional activation of the human NOS2 gene by cytokines (TNF-α, IL-1β, IFN-γ) was demonstrated by nuclear run-on analysis; functional cytokine-responsive promoter elements were identified in three distinct regions located between −3.8 and −16 kb upstream of the gene, markedly distinct from the murine iNOS promoter where only 1 kb of 5'-flanking sequence is required.\",\n      \"method\": \"Nuclear run-on transcription assay, luciferase reporter transfection with deletion constructs up to −16 kb\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — nuclear run-on plus systematic promoter deletion analysis\",\n      \"pmids\": [\"8577713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Crystal structures of human iNOS catalytic (heme) domain at 2.25 Å revealed active-site residues nearly identical to those of eNOS; both structures show a structural zinc atom at the dimer interface coordinated by four cysteines (two from each monomer), establishing this zinc-tetrathiolate center as a conserved element of NOS dimer stability.\",\n      \"method\": \"X-ray crystallography at 2.25 Å resolution, comparison with eNOS structure\",\n      \"journal\": \"Nature structural biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with cross-isoform structural comparison\",\n      \"pmids\": [\"10074942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Crystal structures of the heme domain of human NOS2 in zinc-free and zinc-bound states revealed that: (i) in the zinc-free form, two symmetry-related cysteines form a disulfide bond; (ii) in the zinc-bound form, the same cysteines constitute a ZnS4 (zinc-tetrathiolate) center identical to that in NOS3, which stabilizes intersubunit contacts and maintains the integrity of the tetrahydrobiopterin (BH4) binding site.\",\n      \"method\": \"X-ray crystallography of zinc-free and zinc-bound NOS2 heme domain, structural comparison with NOS3\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — two independent crystal structures with explicit functional interpretation of zinc coordination\",\n      \"pmids\": [\"10409685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Functional promoter analysis with constructs linked to the thymidine kinase promoter identified that the human NOS2 gene requires promoter sequences up to −16 kb for full cytokine inducibility; the human iNOS promoter architecture contrasts substantially with the murine promoter, which requires only ~1 kb.\",\n      \"method\": \"Luciferase reporter assays with NOS2-TK promoter fusions up to −16 kb in cytokine-stimulated AKN-1 hepatic cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic promoter deletion analysis with quantitative reporter readout\",\n      \"pmids\": [\"8577713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Histone deacetylase 2 (HDAC2) directly interacts with NF-κB p65 and promotes cytokine-induced NOS2 transcription; HDAC inhibition with trichostatin A suppressed iNOS promoter activity without altering NF-κB DNA binding, and HDAC2 overexpression enhanced both NOS2 and NF-κB element promoter activity.\",\n      \"method\": \"Co-immunoprecipitation, GST pull-down, transient transfection reporter assays, Griess reaction for NO, gel shift/supershift assays\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP and direct GST pull-down identifying HDAC2–p65 interaction, with multiple functional readouts\",\n      \"pmids\": [\"12138131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"NOS2 protein expressed in skeletal muscle of septic patients undergoes tyrosine nitration by peroxynitrite on selected tyrosine residues, and in vitro nitration of NOS2 by peroxynitrite decreases its enzymatic activity, identifying tyrosine nitration as a post-translational mechanism of NOS2 self-inhibition.\",\n      \"method\": \"In vitro peroxynitrite treatment, Western blot, immunoprecipitation, NOS activity assay in human skeletal muscle from septic patients\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct in vitro enzyme inactivation correlated with in vivo nitration, but single-lab study\",\n      \"pmids\": [\"12097137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"An S714P mutation in NOS2 identified in Dahl/Rapp salt-sensitive rats reduces enzyme stability post-translationally (shorter protein half-life), resulting in decreased NOS2 protein levels and reduced nitrite production; a proteasomal mechanism is implicated, and the functional deficit is overcome by L-arginine supplementation.\",\n      \"method\": \"Transient transfection of COS-7 cells with wild-type and mutant NOS2 cDNA, metabolic labeling (pulse-chase), immunoblot, nitrite production assay\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in heterologous cells with metabolic labeling establishing reduced half-life as mechanism\",\n      \"pmids\": [\"11509447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NOS2-derived NO regulates NF-κB activity by S-nitrosylating the p65 subunit at a conserved cysteine within the Rel homology domain; this inhibits NF-κB-dependent gene transcription, and nuclear levels of S-nitrosylated p65 correlate with decreased p50-p65 DNA binding, establishing a negative feedback loop in which NOS2 attenuates its own expression.\",\n      \"method\": \"S-nitrosylation detection, site-directed mutagenesis of p65 cysteine, NF-κB reporter assays, ChIP for NOS2 promoter binding, cytokine stimulation of respiratory epithelial cells and macrophages\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct identification of S-nitrosylation site by mutagenesis, multiple orthogonal methods including ChIP\",\n      \"pmids\": [\"17720813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Crystal structures of NOS isoforms with inhibitor-bound conformations revealed an isozyme-specific induced-fit binding mode: a cascade of conformational changes in second- and third-shell residue triads opens an isoform-specific specificity pocket; this 'anchored plasticity' mechanism provides the structural basis for selective iNOS inhibitor design.\",\n      \"method\": \"X-ray crystallography of NOS-inhibitor complexes, mutagenesis of second/third-shell residues, inhibitor binding assays\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple crystal structures combined with mutagenesis establishing induced-fit mechanism\",\n      \"pmids\": [\"18849972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"iNOS (NOS2) is required for normal wound closure; iNOS knockout mice show a 31% delay in excisional wound repair that is fully reversed by single topical application of an adenoviral vector expressing human iNOS cDNA, establishing a direct, gene-specific role for iNOS-derived NO in wound healing.\",\n      \"method\": \"iNOS knockout mice, adenoviral gene transfer (AdiNOS), wound closure measurement, RT-PCR for iNOS mRNA, pharmacological iNOS inhibition\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout rescued by gene replacement, with pharmacological corroboration\",\n      \"pmids\": [\"9486966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"iNOS-deficient fibroblasts exhibit reduced proliferation, decreased collagen synthesis, and slower matrix contraction compared to wild-type; collagen synthesis is restored by NO donors, demonstrating that iNOS-derived NO is required cell-autonomously for fibroblast functions critical to wound healing.\",\n      \"method\": \"iNOS knockout mouse fibroblast explant culture, [3H]-thymidine incorporation, [3H]-proline incorporation into collagenase-sensitive protein, fibroblast-populated collagen lattice contraction assay, NO donor rescue\",\n      \"journal\": \"Surgery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with multiple cellular phenotypes and chemical rescue\",\n      \"pmids\": [\"11490353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Genetic deletion of NOS2 in APP Swedish mutant mice results in hyperphosphorylation of mouse tau, its redistribution to somatodendritic compartments, and aggregate formation, as well as increased insoluble Aβ, neuronal degeneration, and caspase-3 activation; NO acts at a junction point connecting Aβ pathology, caspase activation, and tau aggregation.\",\n      \"method\": \"Bigenic mouse model (APP/NOS2−/−), immunohistochemistry, Western blot, tau phosphorylation assays, caspase-3 activation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in bigenic knockout model with multiple molecular phenotypes\",\n      \"pmids\": [\"16908860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Proteomic analysis of the NOS2 interactome in human airway epithelial cells identified FBXO45 as a novel direct NOS2 interactor that requires Asn27 in the 23DINNN27 motif of NOS2 (same as SPSB proteins) but recruits a distinct E3 ubiquitin ligase complex (MYCBP2/SKP1); cytokine-inducible NOS2 interactions with allosteric activators and the ubiquitin-proteasome system correlated with increased NOS2 ubiquitination and NO output.\",\n      \"method\": \"Flag-tag Co-IP, SILAC quantitative MS, direct interaction validation, cytokine stimulation, NOS2 ubiquitination assay\",\n      \"journal\": \"Nitric oxide : biology and chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — SILAC interactome plus direct interaction validation with motif mutagenesis implied by comparison with SPSB data\",\n      \"pmids\": [\"23438482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"iNOS is targeted to peroxisomes in hepatocytes through interaction with the peroxisomal import protein PEX7 and the adaptor protein EBP50; siRNA knockdown of PEX7 reduced iNOS–peroxisomal colocalization, and iNOS peroxisomal targeting was contingent on EBP50 expression in LPS-treated mice, identifying a novel subcellular targeting pathway for NOS2.\",\n      \"method\": \"siRNA knockdown, confocal microscopy, immunoelectron microscopy, MALDI-MS proteomics, Co-IP, in vivo LPS model\",\n      \"journal\": \"Nitric oxide : biology and chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (EM, confocal, MS, siRNA) confirming peroxisomal localization mechanism in vitro and in vivo\",\n      \"pmids\": [\"23474170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"iNOS-generated NO is required for transdifferentiation of fibroblasts to endothelial cells; upon NFκB-dependent iNOS induction, iNOS translocates to the nucleus and S-nitrosylates the polycomb repressive complex member RING1A at Cys398, reducing RING1A chromatin binding and global H3K27 trimethylation; expression of a C398A RING1A mutant nearly abolished transdifferentiation.\",\n      \"method\": \"iNOS KO murine embryonic fibroblasts, siRNA knockdown, iNOS overexpression, immunostaining for nuclear iNOS, Co-IP, mass spectrometry for S-nitrosylation site, H3K27me3 ChIP, transdifferentiation efficiency assay\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — site-specific S-nitrosylation identified by MS and confirmed by mutagenesis, combined with genetic KO and rescue\",\n      \"pmids\": [\"27623813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In TLR4-activated microglia, de novo upregulated Sur1-Trpm4 channels regulate NOS2 transcription via the calcineurin (CN)/NFAT pathway; pharmacological or genetic inhibition of Sur1-Trpm4 increased [Ca2+]i but caused phosphorylation of CaMKII and CN (inactivating CN), reduced NFAT nuclear translocation, and suppressed NOS2 mRNA and protein, as confirmed by chromatin immunoprecipitation.\",\n      \"method\": \"In vivo and in vitro microglia from WT, Abcc8−/−, Trpm4−/− mice; siRNA gene silencing; patch clamp; calcium imaging; ChIP for NFAT at Nos2 promoter; Griess assay; qPCR; Western blot\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models, ChIP, and electrophysiology establishing Sur1-Trpm4→CN/NFAT→NOS2 pathway\",\n      \"pmids\": [\"27246103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LACC1 converts L-citrulline (the NOS2 byproduct) to L-ornithine and isocyanic acid, bridging NOS2 activity to polyamine biosynthesis (via ODC1) in inflammatory macrophages; LACC1 phenotypes in Salmonella-infected bone marrow-derived macrophages required upstream NOS2 and downstream ODC1, and chemical complementation with L-ornithine rescued Lacc1−/− activity.\",\n      \"method\": \"Lacc1−/−, Nos2−/−, Odc1−/− mouse models; bone marrow-derived macrophage Salmonella infection; biochemical enzyme assay; L-ornithine complementation; genetic epistasis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — enzyme reconstitution identifying the L-citrulline→L-ornithine reaction, supported by genetic epistasis across three knockout models and chemical rescue\",\n      \"pmids\": [\"35978195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NOS2 expression and associated NO signaling induces DNA hypomethylation by promoting degradation of DNMT1 through an NO/p38-MAPK/KAT5-dependent mechanism; this results in LINE-1 retrotransposon hypomethylation, expression, DNA damage, and malignant epithelial transformation.\",\n      \"method\": \"NOS2 overexpression and knockout in human cell lines, NO donor treatment, DNMT1 protein stability assay, p38-MAPK inhibition, KAT5 pathway analysis, bisulfite sequencing, LINE-1 expression and DNA damage assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic pathway defined by multiple inhibitors and genetic tools with direct measurement of DNMT1 degradation and epigenetic outputs\",\n      \"pmids\": [\"35584114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"A polymorphic (CCTTT)n pentanucleotide repeat in the NOS2A promoter differentially drives NOS2 transcription; the 14-repeat allele showed strongest IL-1β-inducible luciferase activity and was least inhibited by high-glucose conditions, demonstrating that promoter microsatellite length functionally modulates NOS2 expression.\",\n      \"method\": \"Luciferase reporter assay in transfected colonic carcinoma cells with different (CCTTT)n repeat constructs under IL-1β stimulation and high-glucose conditions\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional promoter assay; single-lab study in one cell type\",\n      \"pmids\": [\"10506586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Rho GTPase signaling regulates NOS2 at a post-transcriptional level: inhibition of ROCK (Rho-associated kinase) with Y-27632 decreased NOS2 promoter activity yet increased NOS2 mRNA and protein levels, indicating that ROCK-mediated suppression operates downstream of transcription initiation at the message and protein level, independently of prenylation-mediated effects on the NOS2 promoter.\",\n      \"method\": \"Pharmacological inhibition of HMG-CoA reductase, geranylgeranyl pyrophosphate rescue, ROCK inhibitor (Y-27632), NOS2 promoter-luciferase, NOS2 mRNA and protein quantitation in human alveolar epithelial cells\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pathway inhibitors dissecting promoter vs. post-transcriptional regulation; single-lab study\",\n      \"pmids\": [\"12169580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A homozygous frameshift mutation in NOS2 causing a truncated, catalytically inactive NOS2 protein (no NO production) was identified in a human patient with fatal CMV disease, establishing that inherited NOS2 deficiency causes selective susceptibility to CMV in humans while being otherwise clinically silent.\",\n      \"method\": \"Whole-exome sequencing, functional testing of truncated mutant (no NO production), population-level analysis of NOS2 homozygous variants in public databases\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — human genetic loss-of-function with direct demonstration of absent enzymatic activity\",\n      \"pmids\": [\"31995689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NOS2 enhances KRAS-driven lung tumorigenesis: KRAS(G12D);NOS2 knockout mice showed delayed lung tumor development, reduced tumor cell proliferation, suppressed macrophage recruitment, and markedly decreased miR-21 expression in lung carcinomas compared to KRAS(G12D);NOS2 wild-type controls, demonstrating cooperative action of NOS2 and oncogenic KRAS in driving lung cancer via miR-21-dependent Ras signaling amplification.\",\n      \"method\": \"Genetic crosses of NOS2 KO with KRAS(G12D) mouse model, tumor histology, proliferation assays, macrophage infiltration analysis, qRT-PCR, in situ hybridization for miR-21\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic epistasis in transgenic cancer model with multiple defined molecular phenotypes\",\n      \"pmids\": [\"22618808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In a mannan-induced psoriatic arthritis mouse model, macrophage NOS2-derived NO promotes arthritis by triggering IL-1α release from skin macrophages, which then drives IL-17 production by innate lymphoid cells; Nos2 deletion or pharmacological NOS inhibition (L-NAME) suppressed disease, placing NOS2 upstream of IL-1α and the IL-17 innate lymphocyte axis.\",\n      \"method\": \"Nos2−/− mice, mannan-induced psoriatic arthritis model, Nos2-selective and general NOS inhibitors, IL-1α and IL-17 quantitation, monocyte subset analysis from PsA patients\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout combined with pharmacological inhibition and mechanistic cytokine pathway placement\",\n      \"pmids\": [\"29774240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NOS2 in ER-negative breast cancer cells is feed-forward regulated by hypoxia, serum withdrawal, IFN-γ, and exogenous NO; NOS2-derived NO upregulates S100A8, IL-6, IL-8, and TIMP-1, enhances cellular migration and chemoresistance to Taxol, and promotes brain metastasis; NOS2 inhibition in MDA-MB-231 xenografts suppressed tumor growth and metastasis.\",\n      \"method\": \"NOS2 inhibitor treatment and shRNA knockdown in ER− breast cancer cells, xenograft mouse model, fat-pad-to-brain metastasis assay, cytokine/chemokine profiling, Taxol chemoresistance assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanistic studies corroborated by in vivo xenograft genetic/pharmacological experiments\",\n      \"pmids\": [\"24733928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NOS2-derived NO mediates glioma stem cell (GSC) proliferation and tumorigenicity; NOS2 is elevated in GSCs relative to non-GSCs and normal progenitors, NOS2 inhibition selectively impairs GSC growth and intracranial tumor formation, and NOS2-regulated genes include the cell-cycle inhibitor CDA1.\",\n      \"method\": \"NOS2 inhibitor (1400W) treatment, NOS2 shRNA in GSC cultures, murine intracranial glioma model, gene expression profiling, CDA1 identification\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple loss-of-function approaches in vitro and in vivo with pathway gene identification\",\n      \"pmids\": [\"21729780\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NOS2 (iNOS) is a calcium-independent, transcriptionally inducible enzyme that converts L-arginine to NO and L-citrulline using FMN, FAD, NADPH, heme, and tetrahydrobiopterin cofactors; its homodimer is stabilized by a zinc-tetrathiolate center; it is transcriptionally activated by NF-κB, STAT-1α, NFAT (via Sur1-Trpm4/calcineurin signaling), and HDAC2–NF-κB complexes through promoter elements up to −16 kb in humans, and is post-transcriptionally regulated by a network of RNA-binding proteins; NOS2 activity is subject to negative feedback via S-nitrosylation of NF-κB p65 (at a conserved Rel-domain cysteine) and auto-nitration of NOS2 tyrosine residues by peroxynitrite; NOS2 protein stability is regulated post-translationally (proteasomal degradation via FBXO45/MYCBP2 E3 complex; S714 phosphorylation status); subcellular targeting to peroxisomes is mediated by PEX7 and EBP50; NOS2-derived NO exerts pleiotropic downstream effects including S-nitrosylation of RING1A to relieve polycomb-mediated epigenetic repression during transdifferentiation, DNMT1 degradation via p38-MAPK/KAT5 causing DNA hypomethylation and LINE-1 retrotransposon activation, bridging to polyamine metabolism through LACC1-mediated conversion of L-citrulline to L-ornithine, and negative feedback on NF-κB; physiologically, NOS2 is required for wound healing (collagen synthesis, fibroblast proliferation, matrix contraction), bone fracture repair, anti-CMV immunity, and suppression of tau hyperphosphorylation, while pathologically driving neuroinflammation, psoriatic arthritis (via macrophage IL-1α→innate lymphocyte IL-17), and cancer progression in KRAS-mutant lung cancer and ER-negative breast cancer.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NOS2 (inducible nitric oxide synthase, iNOS) is a cytokine- and pathogen-inducible enzyme that catalyzes sustained high-output production of nitric oxide (NO) from L-arginine, functioning as a central effector in innate immunity, tissue repair, and epigenetic reprogramming. NOS2 transcription is activated by combinatorial cytokine signaling (TNF-α, IL-1β, IFN-γ) through distal enhancer elements extending to −16 kb upstream and is regulated by NF-κB, NFAT, and HDAC2-containing complexes, while enzyme turnover is controlled post-translationally by FBXO45/MYCBP2-mediated ubiquitin-proteasomal degradation and by peroxynitrite-dependent tyrosine nitration that attenuates catalytic activity [PMID:8577713, PMID:27246103, PMID:12138131, PMID:23438482, PMID:12097137]. Beyond canonical antimicrobial NO production—demonstrated by the susceptibility of humans with homozygous NOS2 loss-of-function to fatal CMV infection [PMID:31995689]—NOS2-derived NO drives macrophage IL-1α/IL-17 inflammatory circuits, promotes wound and fracture healing, channels its L-citrulline byproduct through LACC1 to polyamine biosynthesis, and exerts nuclear epigenetic effects by S-nitrosylating the Polycomb repressor RING1A to relieve H3K27me3 silencing and by inducing p38-MAPK/KAT5-dependent DNMT1 degradation to cause DNA hypomethylation [PMID:29774240, PMID:9486966, PMID:15894526, PMID:35978195, PMID:27623813, PMID:35584114]. NOS2 activity is context-dependent in disease: it promotes breast cancer metastasis and chemoresistance through feed-forward induction of pro-tumorigenic cytokines, while its loss in amyloid precursor protein transgenic mice exacerbates tau pathology and neurodegeneration [PMID:24733928, PMID:16908860].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing that human NOS2 transcriptional induction requires distal enhancer elements (up to −16 kb) resolved a key species difference from the murine promoter and defined the architecture for cytokine-responsive regulation.\",\n      \"evidence\": \"Nuclear run-on assays and serial deletion reporter constructs in human liver epithelial cells\",\n      \"pmids\": [\"8577713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific transcription factors binding each distal enhancer not mapped\", \"Chromatin accessibility at these regions in primary human macrophages unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating that NOS2 knockout impairs wound healing and cardiac allograft outcomes—with adenoviral rescue reversing wound defects—established iNOS-derived NO as a physiologically required effector in tissue repair and transplant immunology.\",\n      \"evidence\": \"iNOS knockout mice in wound closure and cardiac transplant models with gene-transfer rescue\",\n      \"pmids\": [\"9486966\", \"9811327\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream NO targets mediating wound repair not identified\", \"Mechanism of opposing acute vs. chronic transplant effects unresolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showing that combinatorial cytokine stimulation (TNF-α + IFN-γ + LPS) is required for NOS2 induction, and that a promoter pentanucleotide repeat polymorphism modulates transcriptional output, defined the signal integration logic governing NOS2 expression.\",\n      \"evidence\": \"Adipocyte and colonic carcinoma reporter assays with individual and combined stimuli\",\n      \"pmids\": [\"10198298\", \"10506586\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic basis of repeat-length-dependent transcription not defined\", \"In vivo relevance of CCTTT repeat variants to disease susceptibility not established\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identifying that the S714P mutation destabilizes NOS2 protein via proteasomal degradation, and that iNOS-derived NO is required for fibroblast proliferation and collagen synthesis, delineated both post-translational control and effector cell biology of NOS2.\",\n      \"evidence\": \"Site-directed mutagenesis with metabolic labeling in COS-7 cells; iNOS KO fibroblast cultures with NO donor rescue\",\n      \"pmids\": [\"11509447\", \"11490353\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase responsible for S714-dependent degradation not identified at this stage\", \"Signaling pathway from NO to collagen synthesis not mapped\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery that HDAC2 positively regulates NOS2 transcription via NF-κB p65 interaction, and that peroxynitrite-mediated tyrosine nitration attenuates NOS2 catalytic activity in septic human muscle, established dual-layer control at both promoter and enzyme activity levels.\",\n      \"evidence\": \"Co-IP/GST pulldown of HDAC2-p65 with NOS2 promoter reporters; peroxynitrite treatment of purified NOS2 with MS validation in patient tissue\",\n      \"pmids\": [\"12138131\", \"12097137\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific nitrated tyrosine residues responsible for activity loss not individually tested by mutagenesis\", \"Whether HDAC2-NF-κB regulation operates in primary macrophages not confirmed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Extending the tissue-repair role of NOS2 to bone, iNOS gene deletion impaired fracture healing by 30–70%, reversed by adenoviral iNOS delivery, confirming NO as a general tissue repair signal.\",\n      \"evidence\": \"iNOS KO mice with femoral osteotomy and biomechanical testing plus adenoviral rescue\",\n      \"pmids\": [\"15894526\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Osteoblast vs. inflammatory cell contribution to local NO not dissected\", \"Downstream NO signaling cascade in osteogenesis undefined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Crossing NOS2 knockout with APP transgenic mice revealed that NOS2-derived NO restrains tau hyperphosphorylation and Aβ accumulation, positioning NOS2 at a nexus of AD-relevant pathology.\",\n      \"evidence\": \"Bigenic NOS2−/− × APPSw mice with phospho-tau, Aβ, and caspase-3 assays\",\n      \"pmids\": [\"16908860\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular target of NO in tau phosphorylation cascade unknown\", \"Relevance to human sporadic AD not tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of peroxisomal targeting via PEX7/EBP50 and of FBXO45/MYCBP2 as the E3 ligase complex governing NOS2 ubiquitin-proteasomal degradation via the DINNN motif defined both the subcellular compartmentalization and turnover machinery of NOS2.\",\n      \"evidence\": \"siRNA knockdown of PEX7 with confocal/immunoEM localization; SILAC MS interactome with ubiquitination assays and DINNN motif mutagenesis\",\n      \"pmids\": [\"23474170\", \"23438482\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of peroxisomal NOS2 (local NO targets) unknown\", \"Whether FBXO45-mediated degradation is dynamically regulated by cytokine signals not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating that NOS2 drives breast cancer metastasis and chemoresistance through feed-forward induction of S100A8, IL-6, IL-8, and TIMP-1 established NOS2 as a pro-tumorigenic effector in aggressive breast cancer.\",\n      \"evidence\": \"NOS2 inhibition in MDA-MB-231 cells and xenograft fat-pad-to-brain metastasis model\",\n      \"pmids\": [\"24733928\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs. paracrine NO effects on metastatic niche not resolved\", \"Patient-stratified clinical relevance of NOS2 inhibition not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Two studies resolved upstream and downstream nuclear signaling: Sur1-Trpm4 channel control of Ca²⁺/calcineurin/NFAT-dependent NOS2 transcription in microglia, and nuclear iNOS S-nitrosylation of RING1A at Cys398 to relieve H3K27me3 repression during cell transdifferentiation, revealing NOS2 as both a transcriptional target and a direct epigenetic modifier.\",\n      \"evidence\": \"ChIP for NFAT at NOS2 promoter with Ca²⁺ imaging and electrophysiology; MS identification of RING1A S-nitrosylation site with C398A mutagenesis abolishing transdifferentiation\",\n      \"pmids\": [\"27246103\", \"27623813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full repertoire of nuclear S-nitrosylation targets of iNOS not catalogued\", \"Whether RING1A nitrosylation occurs in immune cells beyond transdifferentiation unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placing NOS2 upstream of IL-1α release and IL-17 production in a psoriatic arthritis model, with validation in human patient monocytes, established NOS2 as a driver of IL-1α/IL-17 inflammatory circuits.\",\n      \"evidence\": \"Nos2 KO and L-NAME treatment in mannan-induced arthritis model; human PsA monocyte profiling\",\n      \"pmids\": [\"29774240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which NO triggers IL-1α release not defined\", \"Whether NOS2 inhibition is therapeutic in human PsA not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A homozygous NOS2 loss-of-function frameshift in a human patient causing fatal CMV susceptibility proved that NOS2-derived NO is non-redundantly required for human antiviral defense, the first Mendelian disease attributed to NOS2.\",\n      \"evidence\": \"Whole-exome sequencing with biochemical validation of truncated non-functional NOS2 protein\",\n      \"pmids\": [\"31995689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether heterozygous carriers have intermediate CMV susceptibility unknown\", \"Breadth of pathogen susceptibility beyond CMV not characterized\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Three discoveries expanded NOS2 biology: LACC1 converts the NOS2 byproduct citrulline to ornithine for polyamine synthesis in macrophages; NOS2-derived NO degrades DNMT1 via p38-MAPK/KAT5 causing DNA hypomethylation and transformation; and brown adipocyte-derived exosomal iNOS exacerbates cardiac fibrosis.\",\n      \"evidence\": \"Biochemical reconstitution of LACC1 + triple-KO epistasis in Salmonella infection; DNMT1 stability assays with bisulfite sequencing; brown adipocyte ADRB3 KO with exosome transfer to cardiac fibroblasts\",\n      \"pmids\": [\"35978195\", \"35584114\", \"35652349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LACC1-polyamine axis operates in human macrophages not shown\", \"Relative contributions of DNMT1 degradation vs. RING1A nitrosylation to NOS2-driven epigenetic change not compared\", \"Exosomal iNOS cargo selection mechanism unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full catalog of nuclear S-nitrosylation substrates of iNOS, the functional role of peroxisomal NOS2 localization, the therapeutic potential of NOS2 modulation in cancer and autoimmunity, and whether LACC1-mediated citrulline-to-ornithine conversion operates in human inflammatory macrophages.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Nuclear S-nitrosylation target repertoire beyond RING1A uncharacterized\", \"Peroxisomal NO signaling targets unknown\", \"No structural model of human NOS2 regulation by FBXO45/MYCBP2\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 3, 5, 7, 9, 19, 20]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [17, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005777\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [7, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [18, 19, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 16, 21]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [17, 21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FBXO45\",\n      \"MYCBP2\",\n      \"PEX7\",\n      \"EBP50\",\n      \"RING1A\",\n      \"HDAC2\",\n      \"LACC1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"NOS2 (inducible nitric oxide synthase, iNOS) is a calcium-independent homodimeric enzyme that oxidizes L-arginine to nitric oxide (NO) and L-citrulline using FMN, FAD, NADPH, heme, and tetrahydrobiopterin cofactors, with dimer stability maintained by a zinc-tetrathiolate center at the subunit interface [PMID:10074942, PMID:10409685]. Transcription of the human NOS2 gene requires cytokine-responsive promoter elements extending up to −16 kb and is driven by NF-κB, STAT-1α, NFAT (via Sur1-Trpm4/calcineurin signaling), and HDAC2–NF-κB complexes, while NOS2-derived NO feeds back to inhibit its own expression through S-nitrosylation of NF-κB p65 at a conserved Rel-domain cysteine [PMID:8577713, PMID:12138131, PMID:27246103, PMID:17720813]. NOS2 protein turnover is regulated by proteasomal degradation via the FBXO45/MYCBP2 E3 ubiquitin ligase complex, and NOS2 is targeted to peroxisomes through PEX7 and EBP50 [PMID:23438482, PMID:23474170]. Downstream, NOS2-derived NO drives wound healing, collagen synthesis, and fibroblast proliferation [PMID:9486966, PMID:11490353], bridges to polyamine metabolism via LACC1-mediated conversion of L-citrulline to L-ornithine [PMID:35978195], S-nitrosylates RING1A to relieve polycomb-mediated epigenetic repression during transdifferentiation [PMID:27623813], promotes DNMT1 degradation and LINE-1 retrotransposon activation via p38-MAPK/KAT5 [PMID:35584114], and contributes to oncogenesis in KRAS-mutant lung cancer and ER-negative breast cancer [PMID:22618808, PMID:24733928]; inherited complete NOS2 deficiency in humans causes selective susceptibility to cytomegalovirus disease [PMID:31995689].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Molecular cloning from multiple human tissues established that a single human iNOS isoform (NOS2) exists, resolving uncertainty about whether humans express a functional inducible NOS and defining its cofactor requirements (FMN, FAD, NADPH) and calcium-independent catalysis.\",\n      \"evidence\": \"cDNA cloning from hepatocytes, chondrocytes, and DLD-1 cells with heterologous expression in 293 and CHO cells and purified enzyme assays\",\n      \"pmids\": [\"7682706\", \"7504305\", \"7692964\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Calmodulin binding was identified by sequence but its structural role in constitutive activation was not resolved\", \"Tissue-specific splice variants were not excluded\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"NOS2-derived NO was linked to a specific pathophysiological effector function — cytokine-induced suppression of glucose-stimulated insulin secretion in human islets — establishing NO as a mediator of beta-cell dysfunction.\",\n      \"evidence\": \"Human islet culture with cytokine stimulation, L-NMMA inhibition, nitrite assay, cGMP measurement, and EPR spectroscopy\",\n      \"pmids\": [\"8383325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream NO targets in beta cells not identified\", \"Relative contributions of cGMP-dependent vs. cGMP-independent NO signaling not dissected\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Genomic characterization and in vivo expression studies revealed the human NOS2 gene structure (26 exons, chromosome 17q) and showed that constitutive NOS2 expression occurs in airway epithelium and EBV-transformed B cells, overturning the assumption that NOS2 is exclusively inducible.\",\n      \"evidence\": \"Genomic library screening, FISH mapping, in situ hybridization of airway epithelium, RT-PCR/NOS activity in EBV-transformed B cells\",\n      \"pmids\": [\"7509810\", \"7544004\", \"7528106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanisms sustaining constitutive expression in airway epithelium not defined\", \"Whether constitutive expression reflects tonic cytokine signaling was unresolved\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Systematic promoter analysis revealed that full cytokine inducibility of human NOS2 requires upstream sequences extending to −16 kb — far beyond the ~1 kb murine promoter — identifying three distinct cytokine-responsive regions and explaining prior difficulty in reconstituting human iNOS induction.\",\n      \"evidence\": \"Nuclear run-on assays and luciferase reporter constructs with deletions up to −16 kb in cytokine-stimulated AKN-1 hepatic cells\",\n      \"pmids\": [\"8577713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific transcription factors binding the distal elements were not identified\", \"Chromatin architecture at the extended locus not characterized\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Crystal structures of the NOS2 heme domain revealed a zinc-tetrathiolate center at the dimer interface that stabilizes intersubunit contacts and maintains the tetrahydrobiopterin binding site, providing the first structural framework for NOS dimerization and cofactor coupling.\",\n      \"evidence\": \"X-ray crystallography at 2.25 Å of zinc-free and zinc-bound human iNOS heme domains, comparison with eNOS\",\n      \"pmids\": [\"10074942\", \"10409685\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length holoenzyme structure was not obtained\", \"Conformational dynamics during catalytic cycling not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"A polymorphic (CCTTT)n pentanucleotide repeat in the NOS2 promoter was shown to modulate transcriptional output, with the 14-repeat allele conferring maximal IL-1β-inducible activity, linking NOS2 promoter microsatellite variation to functional expression differences.\",\n      \"evidence\": \"Luciferase reporter assays with different repeat-length constructs in colonic carcinoma cells under IL-1β and high-glucose conditions\",\n      \"pmids\": [\"10506586\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell type tested\", \"In vivo relevance of repeat-length variation not demonstrated\", \"Mechanism by which repeat length influences transcription factor binding not defined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Genetic loss-of-function in mice established that NOS2-derived NO is required for wound healing, directly linking iNOS to collagen synthesis, fibroblast proliferation, and matrix contraction — effects rescued by adenoviral NOS2 gene transfer or NO donors.\",\n      \"evidence\": \"iNOS knockout mice with wound closure assays, adenoviral rescue, and iNOS−/− fibroblast cultures with NO donor complementation\",\n      \"pmids\": [\"9486966\", \"11490353\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets of NO in fibroblast collagen synthesis not identified\", \"Relative contributions of macrophage vs. fibroblast NOS2 not separated in vivo\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"An S714P mutation in NOS2 was shown to reduce enzyme stability by accelerating proteasomal degradation, establishing that post-translational protein turnover is a critical determinant of NOS2 activity levels.\",\n      \"evidence\": \"Pulse-chase metabolic labeling in COS-7 cells expressing wild-type vs. S714P NOS2, immunoblot, nitrite assay\",\n      \"pmids\": [\"11509447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The specific E3 ligase responsible was not identified at this time\", \"Whether S714 phosphorylation state regulates wild-type turnover was not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Two post-translational regulatory mechanisms were defined: HDAC2 was identified as a coactivator of NF-κB-dependent NOS2 transcription via direct p65 interaction, and peroxynitrite-mediated tyrosine nitration of NOS2 was shown to decrease its enzymatic activity, establishing auto-inhibitory feedback.\",\n      \"evidence\": \"Co-IP/GST pull-down for HDAC2–p65, reporter assays; in vitro peroxynitrite treatment with NOS activity assay in human skeletal muscle\",\n      \"pmids\": [\"12138131\", \"12097137\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific nitrated tyrosine residues not mapped\", \"HDAC2 recruitment mechanism to the NOS2 promoter in chromatin context not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Rho/ROCK signaling was identified as a post-transcriptional regulator of NOS2, with ROCK inhibition paradoxically increasing NOS2 mRNA and protein despite reducing promoter activity, revealing a previously unrecognized layer of regulation downstream of transcription.\",\n      \"evidence\": \"ROCK inhibitor (Y-27632) and HMG-CoA reductase inhibitor in human alveolar epithelial cells, promoter-luciferase vs. mRNA/protein analysis\",\n      \"pmids\": [\"12169580\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of RNA-binding proteins or mRNA stability factors mediating ROCK effects unknown\", \"Not replicated in other cell types\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Genetic deletion of NOS2 in APP transgenic mice caused tau hyperphosphorylation, somatodendritic redistribution, and neurodegeneration, positioning NOS2-derived NO as a suppressor of tau pathology and connecting NO to the intersection of amyloid and tau biology.\",\n      \"evidence\": \"APP/NOS2−/− bigenic mice, immunohistochemistry, tau phosphorylation and aggregation assays, caspase-3 activation\",\n      \"pmids\": [\"16908860\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular target of NO that modulates tau phosphorylation not identified\", \"Whether the effect is cGMP-dependent or S-nitrosylation-mediated was unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"S-nitrosylation of NF-κB p65 at a conserved Rel-domain cysteine by NOS2-derived NO was shown to inhibit NF-κB DNA binding and NOS2 promoter activity, establishing the molecular basis of a negative feedback loop through which NOS2 attenuates its own transcription.\",\n      \"evidence\": \"S-nitrosylation detection, site-directed mutagenesis of p65 cysteine, NF-κB reporter assays, ChIP in respiratory epithelial cells and macrophages\",\n      \"pmids\": [\"17720813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinetics and reversibility of p65 S-nitrosylation in vivo not determined\", \"Whether denitrosylases regulate this feedback is unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Crystal structures of NOS-inhibitor complexes revealed an isoform-specific induced-fit mechanism ('anchored plasticity') involving second- and third-shell residue triads, providing the structural rationale for designing selective iNOS inhibitors.\",\n      \"evidence\": \"X-ray crystallography of multiple NOS-inhibitor complexes, mutagenesis of specificity-determining residues\",\n      \"pmids\": [\"18849972\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo pharmacokinetic validation of selectivity not reported\", \"Whether the induced-fit mechanism operates similarly in the full-length holoenzyme is unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"NOS2 was shown to sustain glioma stem cell proliferation and tumorigenicity, with NOS2 inhibition selectively impairing GSC growth and intracranial tumor formation, identifying NOS2 as a therapeutic vulnerability in glioblastoma.\",\n      \"evidence\": \"NOS2 inhibitor (1400W) and shRNA in GSC cultures, murine intracranial glioma model, gene expression profiling\",\n      \"pmids\": [\"21729780\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct NO targets in GSC self-renewal not defined\", \"Whether NOS2 is essential in non-GSC tumor bulk was not addressed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Genetic epistasis showed that NOS2 cooperates with oncogenic KRAS to drive lung tumorigenesis via miR-21-dependent Ras signaling amplification, connecting iNOS-derived NO to a specific oncogenic pathway.\",\n      \"evidence\": \"KRAS(G12D)/NOS2 KO mouse crosses, tumor histology, proliferation assays, miR-21 quantitation\",\n      \"pmids\": [\"22618808\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which NO upregulates miR-21 not defined\", \"Relevance to human KRAS-mutant lung adenocarcinoma not directly tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Two key aspects of NOS2 protein regulation were resolved: FBXO45/MYCBP2 was identified as a novel E3 ubiquitin ligase complex targeting NOS2 for proteasomal degradation, and PEX7/EBP50 were shown to mediate NOS2 targeting to peroxisomes, revealing unexpected subcellular compartmentalization.\",\n      \"evidence\": \"SILAC quantitative MS interactome in airway epithelial cells, Flag-tag Co-IP, siRNA knockdown of PEX7, confocal/immunoelectron microscopy, in vivo LPS model\",\n      \"pmids\": [\"23438482\", \"23474170\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of peroxisomal NOS2 on local NO signaling not characterized\", \"Whether FBXO45-mediated degradation is regulated by cytokine signaling remains to be dissected\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"NOS2 was shown to drive ER-negative breast cancer aggressiveness by upregulating pro-metastatic factors (S100A8, IL-6, IL-8, TIMP-1), enhancing migration, chemoresistance, and brain metastasis, positioning NOS2 as a therapeutic target in aggressive breast cancer.\",\n      \"evidence\": \"NOS2 inhibitor and shRNA in MDA-MB-231 cells, xenograft model, fat-pad-to-brain metastasis assay, cytokine profiling\",\n      \"pmids\": [\"24733928\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct NO signaling pathway linking NOS2 to S100A8/IL-6 upregulation not defined\", \"Patient-derived xenograft validation not reported\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Two new signaling pathways converging on NOS2 were defined: Sur1-Trpm4 channels were shown to regulate NOS2 transcription via calcineurin/NFAT in microglia, and NOS2-derived NO was found to S-nitrosylate RING1A at Cys398 to relieve polycomb repression during fibroblast-to-endothelial transdifferentiation, revealing NOS2 as an epigenetic regulator.\",\n      \"evidence\": \"Abcc8−/−, Trpm4−/− microglia with patch clamp, calcium imaging, ChIP for NFAT; iNOS KO fibroblasts with mass spectrometry for RING1A S-nitrosylation site, C398A mutagenesis, H3K27me3 ChIP\",\n      \"pmids\": [\"27246103\", \"27623813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide targets of RING1A derepression by NO not catalogued\", \"Whether Sur1-Trpm4/NFAT axis operates in human microglia not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"NOS2 was positioned upstream of an IL-1α→IL-17 innate lymphoid cell axis in psoriatic arthritis, with macrophage NOS2-derived NO triggering IL-1α release that drives pathogenic IL-17 production.\",\n      \"evidence\": \"Nos2−/− mice, mannan-induced psoriatic arthritis model, pharmacological NOS inhibition, cytokine quantitation, PsA patient monocyte analysis\",\n      \"pmids\": [\"29774240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of NO-induced IL-1α release from macrophages not molecularly defined\", \"Human genetic evidence linking NOS2 variants to PsA not available\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A human NOS2 loss-of-function frameshift mutation causing absent NO production was linked to fatal CMV disease, establishing that NOS2 is essential for anti-CMV immunity in humans while being dispensable for other immune functions.\",\n      \"evidence\": \"Whole-exome sequencing, functional testing of truncated NOS2 mutant, population-level variant analysis\",\n      \"pmids\": [\"31995689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether heterozygous NOS2 deficiency confers partial susceptibility unknown\", \"Mechanism by which NOS2-derived NO controls CMV replication in humans not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Two downstream effector pathways of NOS2 were elucidated: LACC1 was shown to convert the NOS2 byproduct L-citrulline to L-ornithine, bridging NO synthesis to polyamine metabolism in macrophages, and NOS2-derived NO was found to promote DNMT1 degradation via p38-MAPK/KAT5, causing LINE-1 hypomethylation and genomic instability.\",\n      \"evidence\": \"Lacc1−/−, Nos2−/−, Odc1−/− macrophages with Salmonella infection and chemical rescue; NOS2 overexpression/KO with DNMT1 stability assay, bisulfite sequencing, LINE-1 assays\",\n      \"pmids\": [\"35978195\", \"35584114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LACC1 pathway is relevant in non-macrophage cell types unknown\", \"Quantitative contribution of NOS2-driven DNMT1 loss to cancer initiation vs. progression not separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full-length holoenzyme structure of human NOS2, the identity of RNA-binding proteins mediating post-transcriptional regulation, the direct NO targets controlling tau phosphorylation, and the mechanism by which NOS2-derived NO triggers IL-1α release from macrophages.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full-length human NOS2 holoenzyme structure available\", \"Post-transcriptional regulatory network (RNA-binding proteins, miRNA) incompletely defined\", \"Molecular mechanism of NO-mediated suppression of tau hyperphosphorylation unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [14, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0005777\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [16, 17, 27, 29]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [14, 22, 24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [28, 30, 31]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [21, 24]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"NFKB1\",\n      \"RELA\",\n      \"HDAC2\",\n      \"FBXO45\",\n      \"MYCBP2\",\n      \"PEX7\",\n      \"SLC9A3R1\",\n      \"RING1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}